THE EFFECT OF STRONTIUM-CONTAINING SILICON-DOPED HYDROXYAPATITE CERAMICS ON BONE DEFECT HEALING

A THESIS SUBMITTED TO
THE GRADUATE SCHOOL OF NATURAL AND APPLIED SCIENCES
OF
MIDDLE EAST TECHNICAL UNIVERSITY

BY

GÖZDE KERMAN

IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR
THE DEGREE OF DOCTOR OF PHILOSOPHY
IN
BIOTECHNOLOGY

JANUARY 2011
Approval of the thesis:

THE EFFECT OF STRONTIUM-CONTAINING SILICON-DOPED HYDROXYAPATITE CERAMICS ON BONE DEFECT HEALING

submitted by GÖZDE KERMAN in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Department of Biotechnology, Middle East Technical University by,

Prof. Dr. Canan Özgen
Dean, Graduate School of Natural and Applied Sciences

Prof. Dr. İnci Eroğlu
Head of Department, Biotechnology

Prof. Dr. Feza Korkusuz
Supervisor, Physical Education and Sports Dept., METU

Prof. Dr. Mürvet Volkan
Co-Supervisor, Chemistry Dept., METU

Examiing Committee Members:

Prof. Dr. Muharrem Timuçin
Metallurgical and Materials Engineering Dept., METU

Prof. Dr. Feza Korkusuz
Physical Education and Sports Dept., METU

Prof. Dr. Petek Korkusuz
Histology and Embryology Dept., Hacettepe University

Assoc. Prof. Dr. Ayşen Tezcaner
Engineering Sciences Dept., METU

Assoc. Prof. Dr. Caner Durucan
Metallurgical and Materials Engineering Dept., METU

Date: 24.01.2011
I hereby declare that all information in this document has been obtained and presented in accordance with academic rules and ethical conduct. I also declare that, as required by these rules and conduct, I have fully cited and referenced all material and results that are not original to this work.

Name, Last name: Gözde Kerman

Signature:
ABSTRACT

THE EFFECT OF STRONTIUM-CONTAINING SILICON-DOPED HYDROXYAPATITE CERAMICS ON BONE DEFECT HEALING

Kerman, Gözde
Ph.D., Department of Biotechnology
Supervisor: Prof. Dr. Feza Korkusuz
Co-Supervisor: Prof. Dr. Mürvet Volkan

January 2011, 137 pages

Hydroxyapatite (HA) based bioceramics have been developed to treat bone defects for the last 30 years. Doping HA with elements is a common approach to increase mechanical strength, biocompatibility and osteointegrity. Bone morphogenetic protein (BMP)-containing bioceramic composites enhance osteointegrity and induce bone formation. Strontium (Sr) is currently used to treat osteoporosis clinically as this element inhibits bone resorption and stimulates bone formation.

In this study, HA was doped with silicon (Si), Sr, BMP-2 and evaluated in cortical bone defect healing. Ceramics were produced and tested mechanically after characterization. Sr release from ceramics was assessed. Ceramics were further evaluated in in vitro and in vivo conditions.

X-ray diffraction analysis results of HA were in line with the literature and Sr-Si-HA ceramics showed similar intensities with HA. Ceramics had 36.9 to 41.6% porosity. Compression strength of Sr1000-Si-HA ceramics was 117.5 MPa which was more than that of the other groups. Consistent Sr
release was observed in the Sr1000-Si-HA and the Sr250-Si-HA groups. Sr1000-Si-HA and Sr250-Si-HA ceramics showed higher cellular proliferation rates than the other groups in vitro. BMP addition increased alkaline phosphatase activities and DNA amounts. BMP-Sr-Si-HA group presented higher (0.304±0.02 g/cm²) bone mineral density values than the other groups 4 weeks after implantation however differences between groups were not significant in vivo. Sr-Si-HA and BMP-Sr-Si-HA composites stimulated new bone formation at cortical bone defects of tibia according to micro computerized-tomography and histological results. Findings of this study promote future research on Sr containing bioceramics in treatment of orthopedic problems.

Keywords: Hydroxyapatite, Defect healing, Strontium, BMP-2
ÖZ

KEMİKTE DEFEKT İYİLEŞMESİNE STRONSİYUM İÇEREN SİLİSYUM-HİDROKSİAPATİT SERAMİKLERİNİN ETKİSİ

Kerman, Gözde
Doktora, Biyoteknoloji bölümü
Tez Yöneticisi : Prof. Dr. Feza Korkusuz
Ortak Tez Yönetici: Prof. Dr. Mürvet Volkan

Ocak 2011, 137 sayfa

Hidroksiapatit(HA) temelli seramikler kemikte defekt tedavisi için son 30 yıldan beri geliştirilmektedir. HA kırılgan bir yapida olduğu için, mekanik direncinin, biyouyumluluğun artırılması ve kemikle bütünleşmesini sağlamak için çeşitli elementlerle desteklenmeye çalışılmaktadır. Kemik morfogenetik protein(BMP) içeren kompozitler, implantın kemikle bütünleşmesini ve yeni kemik oluşumu arttırmaktadır. Stronsiyum(Sr) kemik rejenerasyonunu teşvik edip, kemik rezorpsiyonunu önlediği için osteoporoz tedavisinde kullanılmaktadır.


HA’nın X ray-difraksiyon testi sonuçları diğer araştırmaların sonuçlarına uyum göstermiştir ve Sr-Si-HA seramiklerinin intensity değerleri HA ile
benzerlik göstermektedir. Seramiklerin gözenekliliklerinin % 36.9-41.6 oranında olduğu tespit edilmiştir. Sr(1000ppm)-Si-HA seramiklerinin kompresyon direnci 117.51 MPa olarak ölçülmiştir ve bu değer karşılaştırılan diğer seramik gruplarınıninkinden daha yüksektir. Sr(1000ppm)-Si-HA ve Sr(250ppm)-Si-HA gruplarında istikrarlı Sr salımı gözlem込まれ. Hücre kültür sonuçlarına göre, Sr(1000ppm)-Si-HA ve Sr(250ppm)-Si-HA seramiklerinin hücresel proliferasyon etkisi diğer gruplardan daha fazla ölçülmüştür. Seramiklere BMP ilavesi ile hücre kültür ortamında alkalen fosfataz (ALP) aktivitesinde ve DNA miktarında artış gözlemmiştir. In vivo deney sonuçlarına göre, implantasyondan 4 hafta sonra, BMP-Sr-Si-HA grubunda diğer gruplara göre daha yüksek kemik mineral yoğunluğu 0.304±0.02 g/cm² olarak gözlemleşmiştir. Ancak grupların BMD değerleri arasındaki farklılıklar istatistiksel olarak anlamlı çıkmamıştır. Buna rağmen mikro bilgisayarlı-tomografi analiz ve histolojik incelemelere göre, BMP-Sr-Si-HA ve Sr-Si-HA seramikleri, tibiadaki kortikal defekt alanlarında yeni kemik oluşumunu diğer gruplara oranla daha çok arttırmıştır. Bu çalışmanın sonuçları ortopedik problemlerin tedavisinde Sr içeren biyoseramiklerin araştırmalarını teşvik etmektedir.

Anahtar Kelimeler: Hidroksiapatit, Defekt iyileşmesi, Stronsiyum, BMP-2
Dedicated to my parents,
ACKNOWLEDGEMENTS

I would like to give my special thanks to Prof. Dr. Feza Korkusuz for his guidance, support and valuable suggestions for my thesis studies.

I also acknowledge Prof. Dr. Petek Korkusuz for her useful suggestions, interest for improving this thesis and giving me permission to study in her lab.

I would like to express my special thanks to Prof. Dr. Hasan Uludağ for his guidance, mentoring, attention, patience and also providing me opportunity to work in his lab.

I would like to extend my thanks to Prof. Dr. Muharrem Timuçin for his suggestions and guidance for this thesis study. And also I acknowledge Assoc. Prof. Dr. Nurşen Koç for her suggestions and patience to my questions about Metallurgical and Materials Engineering.

I wish to express my sincere thanks to Prof. Dr. Murvet Volkan for her suggestions, advices and the extra time she has spent for this thesis.

I acknowledge Cezary Kucharski for his support, guidance at cell culture studies. I would like to thank to Asist. Prof. Dr. Ilkan Tatar for his help and support for micro CT measurements. I wish to express my thanks to Sedat Acar for all his support and goodwill during long hours we worked hard together.

I would like to thank to Murat Kaya, Rumeysa Gürbüz, Eda Öztürk and also to send my thanks to my friends, Nesrine Zakaryia, Vanessa Incani and Ross Fitzsimmons for their help, friendship and support for my thesis study.

I would like to express my sincere thanks to my parents, for their continuous support, help, encouragement, interest, suggestions, thoughtfulness, time and effort they have spent for me.
# TABLE OF CONTENTS

ABSTRACT........................................................................................................................................... iv
ÖZ............................................................................................................................................................ vi
ACKNOWLEDGEMENTS........................................................................................................................ ix
TABLE OF CONTENTS.......................................................................................................................... x
LIST OF TABLES...................................................................................................................................... xiii
LIST OF FIGURES..................................................................................................................................... xiv
LIST OF ABBREVIATIONS..................................................................................................................... xvii

## CHAPTERS

1. INTRODUCTION.............................................................................................................................. 1

1.1. Structure and Function of Bone.................................................................................................. 1

1.2. Bone Metabolism....................................................................................................................... 4

1.3. Osteoporosis................................................................................................................................ 5

1.3.1. Mechanism of Osteoporosis................................................................................................. 5

1.3.2. Economic Importance of Osteoporosis in the World........................................................... 6

1.3.3. Postmenopausal Osteoporosis............................................................................................. 7

1.4. Bone Mineral Density (BMD).................................................................................................... 9

1.5. Biomaterials.................................................................................................................................. 10

1.5.1. Mineral Scaffolds.................................................................................................................. 11

1.5.2. Bioceramics........................................................................................................................... 12

1.6. Bone Morphogenetic Proteins (BMP)...................................................................................... 13

1.7. Strontium...................................................................................................................................... 14

1.8. Research Questions.................................................................................................................... 14

1.9. Hypothesis...................................................................................................................................... 14

1.10. Literature Review and Rational................................................................................................. 15

1.10.1. Osteoporosis Models in Rats............................................................................................... 15

1.10.2. Trials with HA Ceramics..................................................................................................... 16
1.10.3 Trials Related to Defect Healing in Rats.........................19
1.10.4. Trials with BMP-2 for Bone Formation.........................20
1.10.5. Trials with Sr Substituted Bioceramics.........................22

1.11. Originality.................................................................26
1.12. Aims of The Study......................................................27

2. MATERIALS and METHODS ..............................................30

2.1. Design........................................................................30
2.2. Development of The Ceramic Systems..............................31
  2.2.1. Preparation of The Ceramic Systems..........................31
  2.2.2. Material Properties................................................33
    2.2.2.1. X-Ray Diffraction(XRD) Analysis.........................33
    2.2.2.2. Porosity Test..................................................35
    2.2.2.3. Compression Test...........................................37
    2.2.2.4. Scanning Electron Microscopy............................38
  2.3. Sr Release Test...........................................................38
  2.4. In Vitro Experiments..................................................40
    2.4.1. Tests and Microscope Observation for In Vitro
           Experiments.......................................................42
      2.4.1.1. MTT Test....................................................42
      2.4.1.2. ALP Test....................................................43
      2.4.1.3. DNA Test...................................................43
      2.4.1.4. SEM Observation..........................................45
      2.5. In Vivo Experiments..............................................45
        2.5.1. Ovariectomy Operation.....................................46
        2.5.2. Defect Formation..........................................49
        2.5.3. After Defect Formation...................................49
        2.5.4. Tests and Measurements for In Vivo Experiments......50
          2.5.4.1. Micro CT ...............................................50
          2.5.4.2. Histology and Histomorphometry .................51
      2.6. Statistics..................................................................54

3. RESULTS .........................................................................56
3.1. Ceramic Properties

3.1.1. Compression Test

3.2. Sr Release Test

3.3. In Vitro Tests

3.3.1. Proliferation Test by MTT

3.3.2. ALP tests

3.3.3. DNA tests

3.3.4. ALP/DNA Ratio

3.3.5. SEM Images

3.4. In Vivo Tests

3.4.1. Radiology

3.4.1.1. Periosteal Reaction Results

3.4.1.2. Bone Union Results

3.4.1.3. Remodeling Results

3.4.1.4. Implant Integration Results

3.4.1.5. Overall Radiological Scores

3.4.2. DXA Results

3.4.2.1. DXA Results of First Stage Experiments

3.4.2.2. DXA Results of Second Stage Experiments

3.4.3. Micro CT

3.4.4. Histology and Histomorphometry

4. DISCUSSION

5. CONCLUSION

REFERENCES

APPENDIX - ETHICAL COMMITTEE APPROVAL

CURRICULUM VITAE
LIST OF TABLES

TABLES

Table 2.1. Material weights for the preparation of the ceramics ..........................32
Table 2.2. Bulk density (g/cm$^3$) of ceramics used in this study .........................36
Table 2.3. Histological scoring system for tissue response ...............................54
Table 3.1. Compressive strength (MPa) (Ave±SD (Range: Min-Max)) of ceramics assessed in this study .........................................................56
Table 3.2. Sr amount (mg) released from the ceramics into 20 mg distilled water .........................................................................................58
Table 3.3. Bone mineral density (g/cm$^2$) of the Si-HA implanted and defect created tibia Ave±SD (Range: Min-Max) .............................80
Table 3.4. Bone mineral density (g/cm$^2$) of the bioceramic implanted tibia Ave±SD (Range: Min-Max) .........................................................80
Table 3.5. BMD results of the femur to assess OVX and time related changes ......................................................................................................80
Table 3.6. BMD results of the vertebra to assess OVX and time related changes ..................................................................................................80
Table 3.7. Results of histomorphometrical analysis. (defcbt/nbt: ratio of cortical bone thickness at defect area to normal cortical bone thickness, ntb/defarea: ratio of the new trabecular bone area in the defect/total defect area) ........................................83
LIST OF FIGURES

FIGURES

Figure 1.1. Schematic diagram of bone...............................................................2
Figure 1.2. Trabecular thinning related to age...............................................8
Figure 1.3. The groups that were tested in all experiments and their evaluations by radiology, dual energy X-ray absorptiometry, micro-tomography and histology.........................................................29
Figure 2.1. Ceramics that were used in all experiments.................................33
Figure 2.2. XRD graphs of HA, Si-HA, Sr250-Si-HA, Sr500-Si-HA, Sr1000-Si-HA ceramics.................................................................34
Figure 2.3. Porosity percentages of the ceramics assessed in this study..........................................................................................................36
Figure 2.4. Schimadzu mechanical testing machine........................................37
Figure 2.5. SEM images (a,b, c, d) of Si-HA, Sr250-Si-HA, Sr500-Si-HA, Sr1000-Si-HA ceramics.................................................................38
Figure 2.6. LEEMAN-ICP-OES spectrometry and software..........................39
Figure 2.7. Spectrophotometer and the software during measurement..........43
Figure 2.8. Preparation of standard curve samples for the DNA assay.........44
Figure 2.9. Fluroskan Ascent Microplate Fluorometer and Ascent software.................................................................................................................44
Figure 2.10. XP images of rats ........................................................................47
Figure 2.11. DXA machine and appearance of results during measurement.................................................................48
Figure 2.12. The uterus and ligation of the ovaries.........................................48
Figure 2.13. Formation of cortical cavity and filling with bioceramics.........49
Figure 2.14. Micro CT measurement.................................................................51
Figure 2.15. Samples in DeCastro solution........................................................51
Figure 2.16. Semi-enclosed Benchtop Tissue Processor and Modular Tissue Embedding Center…………………………………………51
Figure 2.17. Samples had been embedded with paraffin………………52
Figure 2.18. Sliding microtome that was utilized for taking sections from samples (Samples were collected by microscope slides). ……………………………………………52
Figure 3.1. Compressive strength (MPa) of ceramics assessed in this study………………………………………………………………57
Figure 3.2. Sr release (mg/kg) from ceramics that were incubated in distilled water for 3 and 14 days (n=1 in all groups)…………………58
Figure 3.3. MTT calibration revealed increasing number of cells…………59
Figure 3.4. MTT assay results (a.u.) of cells that were applied to the ceramics…………………………………………………………………………60
Figure 3.5. MTT assay results (a.u.) of cells that were incubated with BMP-containing ceramics……………………………………………………61
Figure 3.6. Photos of ceramics in wells before MTT test at day 1…………62
Figure 3.7. Photos of ceramics in wells before MTT test at day 6…………63
Figure 3.8. Ceramics in wells before the MTT test on day 12………………64
Figure 3.9. ALP assay results (a.u.) of ceramics……………………………65
Figure 3.10. ALP assay results (a.u.) of BMP containing ceramics……….66
Figure 3.11. Standard curve of the DNA assay……………………………68
Figure 3.12. DNA assay results (µg/tablet) of the ceramics…………………69
Figure 3.13. DNA assay results (µg/tablet) of BMP containing ceramics………..70
Figure 3.14. ALP/DNA ratio of cells (a.u./µg) that were incubated with the ceramics………………………………………………………..72
Figure 3.15. ALP/DNA ratio (a.u./µg) of cells that were incubated with BMP-containing ceramics………………………………………………..73
Figure 3.16. SEM pictures of the cells that were incubated with the HA, the Sr250-Si-HA and the Sr500-Si-HA ceramics………………………74
Figure 3.17. Periosteal reaction results of tibiae (control: defect only; control 2: normal bone) of the groups ………………………………75
Figure 3.18. Bone union scores of the tibiae (control: defect only; control 2: normal bone) of the groups ..........................76
Figure 3.19. Remodeling results of tibiae (control: defect only; control 2: normal bone) of the groups ..........................77
Figure 3.20. Implant integration results of tibiae (control: defect only; control 2: normal bone) of the groups ..........................78
Figure 3.21. Overall radiological scores of the tibiae (control: defect only; control 2: normal bone) of the groups. .........................78
Figure 3.22. Micro CT images of the cortical defect into ceramic implanted group (a, b) and normal bones (c, d)...................81
Figure 3.23. Percent bone volume results of samples that were ceramic implanted.................................................................81
Figure 3.24. A to B (HE stained) and C to D (MT stained) show long term (31week) implanted Si-HA ceramics. I: Implant, HE: Hematoxylin & Eosin, MT: Masson’s Trichrome..................82
Figure 3.25. Endochondral (in D) and intramembranous (A-C, E-J) ossification steps are noted within the defect site of implant applied and control groups. I: Implant, NB: New bone, CB: Cortical bone, BM: Bone marrow, Ca: Cartilage, HE: Hematoxylin Eosin, MT: Masson’s Trichrome...............85
Figure 3.26. The defect area is nearly totally ossified in all groups. I: Implant, NB: New bone, CB: Cortical bone, BM: Bone marrow, HE: Hematoxylin Eosin, MT: Masson’s Trichrome........................................86
Figure 4.1. Ca release (mg/kg) from ceramics that were incubated in distilled water for 3 and 14 days (n=2 in all groups)...........91
LIST OF ABBREVIATIONS

ALP  Alkaline Phosphatase Activity
BMU  Basic Multicellular Unit
bFGF Basic Fibroblast Growth Factor
β-TCP beta-Tricalcium Phosphate
BMD  Bone Mineral Density
BMP  Bone Morphogenetic Protein
BSU  Bone Structural Unit
$d_{ \text{bulk}}$  Bulk density
Ca  Calcium
CaP  Calcium Phosphate
CaSR Calcium Sensing Receptor
DNA  Deoxyribonucleic acid
DMSO Dimethylsulfoxide
DXA  Dual X-Ray Absorptiometry
GAG  Glycosaminoglycans
HBSS Hanks’ Balanced Salt Solution
HE  Hematoxylin & Eosin
HA  Hydroxyapatite
ICBM Inactive Collagen Bone Matrix
JCPDS Joint Committee on Powder Diffraction and Standards
M-CSF Macrophage Colony Stimulating Factors
Mg  Magnesium
MT  Masson’s Trichrome
MSC Mesenchymal Stem Cells
Micro CT Micro Computerized Tomography
OB  Osteoblast
Oc  Osteoclast
OVX  Ovariectomy
PTH  Parathyroid hormone
P  Phosphor
PEG  Polyethylene glycol
PLGA  Poly(lactic-co-glycolic acid)
PCR  Polymerase Chain Reaction
RANK  Receptor Activator of Nuclear factor κ β
RANKL  Receptor Activation of Nuclear Factor κ β -Ligand
ROI  Regions Of Interest
SEM  Scanning Electron Microscope
Si  Silicon
Si-HA  Silicon doped Hydroxyapatite
Sr  Strontium
Sr-HA/PEEK  Sr-containing hydroxyapatite/polyetheretherketone
d_th  Theoretical density
3D  Three dimensional
tcps  Tissue culture polystyrene
TGF-β  Tissue Growth Factor-beta
Ti  Titanium
VEGF  Vascular Endothelial Growth Factor
XRD  X-Ray Diffraction
XP  X-Ray picture
1.1. Structure and Function of Bone:

Bone protects internal organs such as the brain, the spinal cord and the lungs and plays a crucial role in hematopoiesis (Kwan et al., 2008). Its functions furthermore include movement and storage of minerals.

Bone is a regenerating tissue whose properties change according to the mechanical requirements of the environment (Bronner et al., 1999). Two types of bone exist at the macrostructure level, viz. cortical (compact) and cancellous (trabecular). Long bones (i.e. humerus, femur, tibia) have a cortical frame at the exterior and a trabecular constitution on the interior (Rho et al., 1998). What differentiates these two types of bone is their porosity and density properties (Carter et al. (1977), Gibson LJ (1985)). Cortical bone is dense and has regular microscopic channels; 80 % of the skeletal mass of the human is cortical bone. Trabecular bone, on the other hand, has a microstructure composed of irregular convolutions of lamellae (Enlow DH, 1963, 1968) and constitutes 20% of the human bone mass (Frost HM (1995), Jee WSS (1999)). The periosteum, the outer fibrous membrane of bones, includes blood vessels and nerve endings. The endosteum, the internal surface, is in contact with marrow, blood vessels, osteoblasts and osteoclasts (Brandi ML, 2009). Haversian canal encompasses blood vessels. Volkmann’s canal which carries arteries does interconnections between Haversian canals and periosteum.
Bone is composed of cells, mineralized extracellular matrix and organic extracellular matrix. Cells are mainly 3 types: osteoblasts (OB), osteocytes and osteoclasts (Oc). OBs, acquired from mesenchymal stem cells (MSC), have a role in depositing calcified matrix and release crucial growth factors for osteogenesis and are also known to organize calcium (Ca) and phosphate to support hydroxyapatite (HA) formation (Manolagas SC, 2000). The Ca sensing receptor (CaSR) is expressed in the proliferation or bone formation
phases of OBs in cultures (Chattopadhyay et al., 2004). When bone formation is complete, OBs are surrounded by a new bone matrix and differentiate into osteocytes. Osteocytes are mechanosensitive cells (Klein-Nulend et al., 1995) remaining within their lacunae deep within the mineralized matrix and are mostly interconnected by their cellular processes. Oc(s) are multinucleated cells by differentiation and fusion of mononuclear-monocyte-macrophage lineage precursors after stimulus by receptor activation of nuclear factor κ β-ligands (RANKL) and macrophage colony stimulating factors (M-CSF) (Boyle et al. (2003), Lacey et al. (1998), Yasuda et al. (1998)). Oc(s) participate in bone remodelling by breaking down the components of bone with the action of lysosomal enzymes as well as low local pH, which facilitates mineral dissolution (Javaid et al., 2008). After osteoclastic bone resorption, osteoblastic bone formation physiologically occurs to fill the defect site and/or repair the defect. The new bone that is formed is named as the Bone Structural Unit (BSU; Frost HM, 1964).

Mineralized extracellular matrix is about 65% of the composition of bone and contains HA. The crystalline mineral component has the following apatitic structure:

\[(Ca,X)(PO_4,HPO_4,CO_3)(OH,Y)\_2\] \hspace{1cm} \text{(Le Geros et al., 2002)}

X designates a cation (Mg, Na or Sr ions that can substitute for Ca ions) and Y designates an anion (Cl\^- or F\^- that can substitute for hydroxyl group (Kim et al. (2003), LeGeros RZ (2002)).

Approximately 35% of bone’s composition is organic extracellular matrix that includes collagen I (as much as 90% by weight) and non-collagenous proteins (osteocalcin, osteopontin, etc). Type I collagen permits bone to absorb energy through plastic deformation without the incidence of bone fracture. Collagen I is also involved in bone mineralization (Caetano-Lopes et al. (2007), Seeman et al. (2006a)). Glycosaminoglycans (GAGs) are proteoglycans that are also found in the bone matrix and have a role in regulation of the mineralization process, i.e., they can inhibit or initiate a
mineralization event under the appropriate conditions (Skerry et al. (1990), Rees et al. (2001)).

Ca, phosphor (P), vitamin D are crucial factors in maintaining a healthy bone mass. Different replacements are found in bone mineral as elements such as Al, Ba, Cu, Cl, F, Fe, Mg, K, Na, Si, Sr, Zn (Driessens et al. (1990), Elliot JC (1994)) and have roles in the biological activity of bone mineral and Ca-P based biomaterials.

1.2. Bone Metabolism:

Formation and resorption of bone at a given site is called Bone Remodelling (Frost HM, 1990). Bone remodelling attempts to alternate aged or damaged bone with new bone to avoid the occurrence of fatigue fractures. Oc(s) remove bone, followed by the deposition of new bone by the OBs (Manolagas SC, 2000). Remodelling usually occurs in the trabecular structure. Oc(s) resorb an amount of bone and OBs replenish the resorption cavity. This process is called the "Basic Multicellular Unit" (BMU) (Gerhard et al., 2009). BMU is a combination that includes Oc(s) in front, OBs at the back, and capillary veins in the centre, together with nerve supply and connective tissue that facilitates the modelling (Parfitt AM, 1994). In healthy people, 3-4 million BMUs are formed per year.

Cortical loss of bone is not that significant before the age of 50, but 40% of trabecular loss can occur before that age (Seeman E, 2008). The vertebral body is wider in males than in females and is stronger in young males than females because of size differences (Seeman E, 1998). Also, the total body bone mineral content of new born babies was observed to be lower in winter births than in summer infants because of maternal vitamin D deficiency (Namgung et al., 1992).
1.3. Osteoporosis:

According to the US National Osteoporosis Foundation, osteoporosis is a condition characterized by low bone mass and the structural deterioration of bone tissue. In 1820, Jean C.F.M. Lobstein coined the term osteoporosis to indicate porous bone (Grob GN, 2010). Increased fragility can be seen most characteristically at the hip, wrist, ribs and spine (Hegge et al., 2009). Vertebral fractures are the most usual osteoporotic fractures found in men and women (O'Neill et al. (1996), Naves-Diaz et al. (2000)). Men run a lifetime risk for osteoporotic fractures of 15%, compared with 40% in women (Vanderschueren et al., 2008).

Accelerated bone loss is higher in women than men and arises due to decreased levels of estrogen (Mullender et al., 2005) because the balance between OBs and Oc(s) is controlled by estrogens (ESHRE Capri Workshop Group, 2010). The estrogen effect occurs as a result of nuclear ligand activated receptors, i.e. estrogen receptor $\alpha$ and $\beta$, that are expressed in bone and cartilage (ESHRE Capri Workshop Group (2010), Venken et al. (2008), Tanko et al. (2008)).

1.3.1. Mechanism of Osteoporosis:

Normal healthy bone has a honeycomb structure while osteoporotic bone has larger holes and spaces in the honeycomb, when inspected at the microscopic level. The morphological properties of osteoporosis are thinning and decrease in the number of the trabeculae (Cummings et al. (2002), Seeman E (2002), Delmas PD (2002)). The reduction in the strength and quality of bone may result in fracture, pain and disability related with osteoporosis (Cooper C, 1997).

In osteoporosis, the lifespan of Oc(s) is extended while the lifespan of OBs is shortened. Therefore, Oc causes resorption and trabecular perforation in the cavities (Manolagas SC, 2000). Bone loss can happen in
two different phases, namely slow or accelerated. In the slow phase, OBs fail to replenish Oc constructed resorption cavities (Riggs et al. (1981, 1986), Parfitt AM (1988)), which results in the gradual thinning of trabeculae (Riggs et al. (1986), Parfitt et al. (1983)). In the accelerated version of bone loss, i.e. postmenopausal bone loss, Oc(s) cause resorption cavities of increased depth, which leads to trabecular perforation.

Receptor activator of nuclear factor κ B (RANK) along with RANKL has a significant role in Oc proliferation and differentiation (Hofbauer et al., 2000). RANKL’s binding with and activation of Oc(s) enhance bone resorption (Boyle et al., 2003).

When the outer load applied to bone surpasses its strength, fracture takes place. The ability of a bone to withstand fracture is related to bone mass, bone macro- and micro-architecture, and the internal properties of the materials that constitute bone (Bouxsein et al., 2005).

1.3.2. Economic Importance of Osteoporosis in the World:

Osteoporosis related fractures are a major health problem affecting a growing number of humans worldwide. In Turkey, as reported by the Turkish Statistical Institute in 2008, 16.1% of people older than 15 years of age had muscle and skeleton problems at their waists, and 13.8% of people older than 15 years of age have rheumatic joint diseases (such as rheumatoid arthritis) (Turkey, Health Interview Survey, 2008).

In 2000, the number worldwide of clinically patented fractures in women was 5.5 million and the peak age for the occurrence of fracture was 75-79 (Johnell et al., 2005). Lifetime endangerment of osteoporotic fractures was 40-50% in women and 13-22% in men (Johnell et al., 2005).

European medical aid costs for osteoporosis were € 31.7 billion in 2000 and are estimated to reach € 76.7 billion in 2050 (Kanis et al., 2005). According to 2006 reports, 1.2 million women had osteoporosis in the UK
(Dennison et al., 2006). One third of people aged above 65 fall every year, with 300,000 fracture cases annually in the UK alone (Martin FC, 2009).

Osteoporosis seriously affects the health of an individual as well as the economy of the country. In 2005, USA osteoporosis related fractures cost 19 billion US$ and are predicted to be 25.3 billion US$ by 2025 according to the National Osteoporosis Foundation. More than 3 million osteoporosis related fractures a year are expected in the United States by 2025, with a yearly cost of 25 million $ (Burge et al., 2007). The rate of hip fractures is 2 to 3 times higher in women than in men in the USA. Patients with difficulty in moving, experience psychological difficulties and are prone to depression, and other undesired consequences.

7753 participant, 50 years of age and older, were investigated for a study as part of an osteoporosis report in Canada (Ioannidis et al., 2009). The participants with hip or vertebral fractures had a higher risk of mortality than others.

1.3.3. Postmenopausal Osteoporosis:

Menopause, aging, inherited factors, low Ca intake and absorption, lack of exercise, excessive alcohol consumption along with smoking are the basic factors that contribute to osteoporosis (Prabha Shankar, 2002).

Postmenopausal osteoporosis is caused by deficiency of estrogen after the cessation of ovulation and results in bone loss and negative balance in bone remodelling (Turner et al., 1994). Women have a faster loss of bone mass during the first 5-10 year after menopause due to the decrease in estrogen (Lindsay R, 1988). Estrogen deficiency causes deprivation of trabecular bone in vertebral bone and the epiphyseal segments of long bone (Westerlind et al., 1997). Estrogen deficiency causes rapid bone resorption and low BMD by stimulating osteoclastic activity (Riggs BL, 1991). Studies with MSC from pre- and postmenopausal women showed that postmenopausal women had a low growth rate of MSC and that the MSC
ability to differentiate along osteogenic lineage was lacking (Rodriguez et al., 1999). In addition, reduced parathyroid hormone (PTH) secretion and increased bone loss results in decreased Ca absorption (Riggs BL, 1991).

Three different phases related to changes in bone mass can occur in life; two of them occur in both sexes, whilst the other is associated only with women (Mazess RB (1982), Parfitt AM (1988)). In the first phase, bone growth and an increase in bone mass can be seen. Linear growth reflects the mineralization of endochondral growth, whereas radial growth is related to rate of periosteal apposition, which exceeds the rate of endosteal resorption. At the age of 20, when the growth plate is closed, radial growth continues until 30 to 35 years of age. The slowing of bone mass starts at around 40 years of age (Riggs et al. (1981,1986), Mazess RB (1982)). The third phase applicable to women is related to the accelerated postmenopausal bone loss because of a lack of estrogen (Riggs et al. (1986), Mazess RB (1982), Lindsay et al. (1980), Genant et al. (1982)).

Figure 1.2. Trabecular thinning related to age.
Postmenopausal osteoporosis can affect women 15-20 years after menopause. Trabecular bone loss in this disease results in fractures especially of vertebrae, and the distal forearm and distal ankle. Although osteoporosis is often considered to be a condition of postmenopausal women, 30% of hip fractures occur in men in the USA according to Hegge et al. (Hegge et al., 2009). Rib fractures are often found to be non-spine fractures in men and can be related to osteoporosis (Barrett-Connor et al., 2010). The preponderance of osteoporosis in men was expected to increase by 50% by 2012 (Looker et al., 1997).

1.4. Bone Mineral Density (BMD):

Approximately 90% of bone mass is accumulated by the age of puberty (Duan et al., 2003). BMD increases through childhood and adolescence. Children and teenagers form new bone faster, and young people continue to make more bone than they lose. After menopause, women’s bone density can drop by 20% or more (National Osteoporosis Foundation, US).

Informing people about the importance of osteoporosis is crucial. Levy et al. tested whether chart reminders or/and patient education can affect BMD testing among women who are 65 years old. According to the results of that study, the educated group of patients had more BMD testing than chart reminders or regular care (Levy et al., 2009). In developed countries, the elderly population is increasing, so osteoporosis prevention has become a crucial socioeconomic priority.

In 1988, Dual x-ray absorptiometry (DXA) instrumentation was developed to determine the bone mineral density (BMD) of an individual in order to gauge the likeliness that they would get osteoporosis (Sanson G, 2003). DXA uses dual energy transmission scanning to generate photons from an X-ray tube (Wahner et al., 1988) and, by measuring BMD, has
become one of the most standard means of diagnosing osteoporotic bone fracture (Hansen et al., 1990).

The T score in DXA (the mean bone mass of a normal young adult reference population) indicates how much bone density is above/below normal and has been used for diagnosing osteoporosis. When the T score is \(-1.0\) or higher, the BMD status of a person is accepted as normal. If the T score is less than \(-1.0\) but higher than \(-2.5\), the status is called osteopenia. When the T score is \(-2.5\) or less, the status is referred to as osteoporosis, according to World Health Organization (Lewiecki EM, 2009).

The Z score (the mean BMD of a person of the same age) is used to equate bone density to what is normal in someone at the same age and body size. A Z score \(<-2.0\) is normal according to the International Society for Chemical Densitometry (ISCD). An older person might have a normal Z score but can be at risk, so using a Z score to measure BMD is not recommended (National Osteoporosis Foundation).

According to Lewiecki, for diagnosis, fracture risk assessment, monitoring during therapy, ionizing radiation and cost, DXA is the best choice when compared with quantitative ultrasonography and quantitative computed tomography (Lewiecki EM, 2009).

BMD measurement is the current standard in osteoporosis. Osteoporosis research teams have taken BMD measurements as a parameter into their study charts (Yoshimura et al. (2010), Hearn et al. (2010)).

1.5. Biomaterials:

Designing and treatment of biodegradable porous three-dimensional structure is called a scaffold (Hutmacher DW, 2000). These scaffolds can become constructive support for cells for tissue regeneration (Lee et al., 2007). Biomaterials can be used to augment bone tissue in the case of osteoporosis, or other needs, for bone regeneration. The release of pharmacological substances over estimated times, with a suitable release
rate from adequately sized and geometrically shaped biomaterials is important in bone regeneration (Krajewski et al., 2000).

The material should be osteoinductive, biocompatible, osteoconductive, and biodegradable if necessary in order to select a biomaterial for bone implantation. Osteoinductive materials induce uncommitted cells (as MSC) to change phenotypically to osteoprogenitor and chondroprogenitor cells. Cellular proliferation qualifies osteogenesis and cellular differentiation characterizes osteoinduction. Osteoconductivity is the ability of the biomaterial to sustain the attachment of cells, new cell migration and angiogenesis into the graft. Biocompatibility means *in vivo* activity of implants without resulting local and/or systemic responses. The necessary properties of the scaffold include adequate porosity, pore interconnection and permeability for the cells to adhere onto and migrate through the scaffold (Evans et al., 2007). Appropriate bulk biomechanical properties are also needed to support mechanical loads and maintain a space with the right porosity (Sanz-Herrera et al., 2009). Application of scaffolds those are geometrically close to bone as alternatives to allografts or autografts is recommended for the treatment of bone defects. Tissue implant interface is critical in dictating the response to biomaterials (Kwan et al., 2007). Osteointegration of biomaterial is related to the properties of biomaterial and regenerative capability, and the characteristics of the host bone (Mori et al., 1997). Cells are dispersed to their contact area after attachment to the implant. Then, migration of the cells and the release of cytokines and extracellular matrix elements start. Cellular attachments to implants are regulated by integrin mediated signal transduction (Gronowicz et al., 1996).

1.5.1. Mineral Scaffolds:

Calcium phosphate (CaP) ceramics, plaster of Paris, bioactive glass can be examples of this group. Ceramics mimic the inorganic composition of
bone with good integration and have high fracture strength (Temenoff et al., 2000).

Ceramics that are used for bone repair can be classified into 3 types (Kamitakahara et al., 2008):

**Bioinert ceramics:** These ceramics form a thin non-adherent fibrous layer at the interface between ceramic and bone. Alumina and zirconia are examples of this group that were used in the head of hip joints because of good mechanical strength and the ability to last for a long time.

**Bioactive ceramics:** These ceramics are osteoconductive. Examples are bioglass, sintered HA ceramics, glass ceramics and wollastonite ceramics.

**Bioresorbable ceramics:** These ceramics can be degraded with time and replaced by natural bone. Tricalcium phosphate (TCP) and calcite (CaCO$_3$) are typical examples.

Cell attachment and proliferation are mostly related with the chemical and physical properties of the surface of a scaffold. Porosity and interconnectivity are important properties of ceramics advised by researchers (Matsumoto et al., 2009). Porous ceramics can be viewed as comprised of individual cells.

1.5.2. Bioceramics:

Ceramics that are used for the treatment of the human body are called bioceramics. Bioceramics can be of bulk form (named implant) used as filler for injured parts or coating materials (Hench et al., 1993). CaP ceramics such as HA and β-TCP have been applied in bone surgery because of the similarity of their chemical composition to the mineral phase of the bone (Le Geros et al., 1993).

95% of the inorganic part of bone is HA and this material can be found synthetically. The gradual dissolution of CaP crystals (HA) results in Ca and phosphate release into biological fluid that is located in ceramic
macrocristals and causes precipitation (Jallot et al., 2000). This precipitation results in the association of bone apatite-like crystals with organic proteins (Daculsi G, 1998).

High porosity is recommended for HA in bone treatment because interconnected pores as a framework for bone growth and good blood-nutritional supply by vascular canal organization prevents implant loosening (Bajpai et al., 2010).

Si (silicon) is found at 100 ppm in bone tissue (Schwarz K, 1973). A significant increase in the effect of Si on BMD in the region was observed when added to the diet of men and postmenopausal women (Jugdaohsingh et al., 2004).

1.6. Bone Morphogenetic Proteins (BMP):

BMPs are dimeric molecules with a single interchain disulfide bond (Reddi AH, 1997). Protein adhesion to minerals is related to the structural properties of proteins. Members of BMPs show good interaction with mineralized matrices (Stayton et al., 2003). BMPs are cytokines that have been identified by their role as stimulating endochondral bone formation (Hogan BL, 1996) because of their osteoinductive property (Kenley et al., 1993). BMP has role in intramembranous and endochondral ossification as chemotaxis and mitosis of mesenchymal cells, osteogenic/chondrogenic differentiation (Reddi AH, 2001).

The most studied growth factors are BMP-2, -4, -5, -6 and -7 (Salata et al., 2002) in the Tissue growth factor (TGF)-β family (Reddi AH (2001), Schmitt et al. (1999)). Growth factors enhance bone healing significantly and stimulate the proliferation and differentiation capacities of MSC (Egermann et al., 2005). According to studies, BMP-2 caused the differentiation of MSC into cells by expressing osteoblastic phenotype (Wozney et al., 1998) and stimulated vascular endothelial growth factor (VEGF) secretion, which causes ectopic bone healing with angiogenesis (Deckers et al., 2002).
1.7. Strontium:

Strontium (Sr) was discovered in 1790 as one of the alkaline earth metals. Sr is a trace element that can be found in calcenous rocks, ocean water (Rosenthal et al. (1970,1972), Schroeder et al. (1972)).

Sr is a trace element in the human body. The amount of Sr is 0.01 – 0.008%, especially in bones and teeth (Aoki et al., 1991), and 98% of total body Sr content is found in the skeleton (Skoryna SC, 1984). Sr is mostly integrated by ionic exchange on bone crystal surfaces (Marie et al., 2001). Most of the dietary Sr is absorbed from jejunum (Marcus et al., 1962).

Sr is close to Ca chemically and physically, so can replace Ca in HA easily (Curzon et al., 1983). Sr can accumulate, especially in trabecular parts of bone (Dahl et al., 2001). The amount of Sr in the skeleton is 3.5% of the Ca molar content (Pors Nielsen S, 2004).

1.8. Research Questions:

The first research question of this study is whether adding Sr into silicon doped hydroxyapatite (Si-HA) ceramics will improve compression strength. The second research question is whether Sr-Si-HA bioceramics will release Sr in time. The third research question is whether Sr-Si-HA ceramics are biocompatible with rat bone marrow stem cells in *in vitro* conditions. The fourth research question is whether Sr-Si-HA ceramics promote bone defect healing when implanted into rat tibia. The final research question is whether adding BMP-2 into the Sr-Si-HA ceramics will improve *in vitro* and *in vivo* biocompatibility.

1.9. Hypothesis:

We assumed that (a) adding Sr into Si-HA will improve the compression strengths of the ceramics, (b) a release of Sr from Sr-Si-HA
ceramics can be observed in time, (c) Sr-Si-HA ceramics are biocompatible with rat bone marrow stromal cells, (d) Sr-Si-HA ceramics improve bone defect healing in rats and (e) adding BMP-2 into HA based ceramics enhances \textit{in vitro} and \textit{in vivo} biocompatibility.

1.10. Literature Review and Rational:

1.10. 1. Osteoporosis Models in Rats:

Rats are relatively cheap, easy growing and have similar skeletal properties to humans (Turner et al., 1987, 1988, 2001).

There are different ways to induce osteoporosis in rats. Glucocorticoid usage is one of them. Glucocorticoid administration resulted in increased bone resorption, decreased bone formation and caused pathological fractures (Dempster DW (1989), Van Staa et al. (2000), Angeli et al. (2006), Hulley et al. (1998), Manolagas SC (2000), Canalis et al. (2002)).

A second means of osteoporosis formation is the application of Heparin to rats. Buriana observed a low decrease in alkaline phosphatase (ALP) activity as a result of heparin (Buruiana et al., 1958). Thompson observed low collagen production by bones by applying Dopaheparin to rats for 8 weeks (Thompson Jr et al., 1973).

Cadmium is a kind of contaminant that damages the kidneys and skeletal system (Chalkley et al. (1998), Satarug et al. (2003), World Health Organisation (WHO-1992), Aoshima et al. (2003), Brzoska et al. (2003), Kawamura et al. (1978), Nordberg et al. (2002), Ohta et al. (2000)). Cadmium affected the mineral phase of bones (Choi et al. (2003), Ogoshi et al. (1989, 1992), Uriu et al. (2000)) in rats. Also, Brzoska applied cadmium to rats for 24 months and observed a reduction in mineral content and abnormalities at trabecules, with a decrease in load bearing abilities (Brzoska et al., 2004a, 2004b).
Alcohol usage is another factor that can induce osteoporosis. Ethanol application resulted in hypocalcemia in rats (Peng et al., 1972, 1974) and also decrease in trabecular bone volume (Saville et al. (1965), Baron et al. (1980)). Turner observed a reduction in tibial bone formation caused by ethanol (Turner et al., 1987).

The separation of gluteal muscle partly or totally from bone resulted in a reduction in trabecular bone mass and thickness (Beery-Lipperman et al., 2005).

Ovariectomy (OVX) in rodents caused a loss of trabecular bone, i.e. an artificial menopause (Ammann et al. (1993), Bagi et al. (1994), Chow et al. (1992), Liu et al. (1990)). Bilateral OVX can be the best choice for postmenopausal osteoporosis development and leads to systemic osteoporosis. According to studies, the bone mineralization level became slower during fracture healing of ovariectomized rats (Xu et al., 2002). Bagi and Çömelekoğlu observed a decrease at femur BMD and femoral cortical thickness (Bagi et al. (1997), Çömelekoğlu et al. (2007)) after OVX. Ovariectomized rats had lower fracture healing rates than controls and callus formation was deprived in those rats (Walsh et al., 1997). Also, OVX with low Ca diet application resulted wrecked late repair at femur in rats (Kubo et al., 1999).

There are several ways for osteoporosis formation. One of the main aims of this study was whether the bioceramic systems can be used for bone healing in postmenopausal women in the future. Ovariectomized rats are mostly used as osteopenic models that imitate the development of estrogen deficiency induced osteopenia in humans (Black et al., 1994). OVX had been preferred for induction of osteoporosis for this purpose.

1.10.2. Trials with HA Ceramics:

Bonding to tissue and anti-corrosion properties of biomedical implants are important properties. An ideal orthopedic implant must be biocompatible,
not allergenic and/or toxic, not affected by sterilization and resistant to high temperatures (Köse N, 2010). Bioactive ceramics are known to improve OB growth and differentiation (Marra et al. (1999), Ambrosio et al. (2001)).

The similarity of HA to the inorganic part of bone and its role in the prevention of Ca resorption was observed firstly in the 1960s in *in vitro* and *in vivo* (Fleisch et al., 1969) experiments. HA is a candidate for hard tissue replacements as stainless steel and ceramic based HA caused good fixation, mostly with no fibrous tissue encapsulation (Bobba R 2006a, 2006b). HA bonds to bone, causing interfering layers, because of its biocompatibility, observed in rats at 4 and 8 weeks (Fujita et al., 2003).

The solubility of porous ceramic bodies in physiological fluids and the chemical and physical contact of porous layers with living tissues are crucial factors for biocompatibility (Krajewski et al., 2000). HA has low biodegradability. Chemical bonding occurs when bone tissue and the HA implant are in contact. Due to its characteristics HA is included in the "bioactive ceramics" group (Zhong et al., 2002). Bioactive ceramics such as sintered calcium HA result in a bioactive response in which tissue ingrowth can occur if the material is porous (Hench et al., 1993). One of the most important considerations in the preparation of porous ceramic preparations is avoiding the possible weakening of scaffolds.

Yokoyama et al. applied HA cylinders to parietal bone and then observed apatite surface formation. Also, bone marrow cells loaded on CaP ceramics were implanted into critical sized defects in rat femurs and complete bone union via accelerated bone healing was seen (Ohgushi et al., 1989).

Researchers prefer HA coating in biomedical implants. Zhou applied HA coating onto hydrogels and grew a cell culture. Higher cell numbers were seen in HA coated hydrogel groups during a 5-day study period (Zhou et al., 2009). Sanz Herrera et al. tested dioxide Zirconium Sponceram® carriers mechanically. When they added HA to Sponceram® carriers, the Youngs Moduli (E) and compression stress increased more significantly than the non HA-coated implants (Sanz Herrera et al., 2008, 2009). In addition, HA
supported with polyethylene was applied to a cell culture and an increase in cell numbers was observed (Bonfield et al., 2002a).

Growth factors have been added into HA scaffolds in order to enhance healing in orthopedic studies. Andreshak applied basic fibroblast growth factor (bFGF)-impregnated Gelfoam and coralline HA to defects that had been constituted by Kerrison rongeur in the tibia of rats. An increase in cartilage volume by bFGF was seen but the healing was not accelerated in the first few days. Although angiogenic effect by bFGF was observed after 2 weeks, the histological appearance of the treated defect was similar to that of the control groups at 4 weeks. Furthermore, according to bending tests, treated groups were weaker than the controls (Andreshak et al., 1997).

According to Carlisle, Si is essential, especially in the early stage of bone calcification, and has a role in the localization of active growth areas (osteoid) in rat bones (Carlisle EM, 1970,1981). The application of a combination of Si with HA (Si-HA) onto a cell culture caused prevention of inflammation and led to an increase of bone formation (Bonfield et al., 2002). Patel applied Si-HA and HA ceramics to laboratory animals and observed more bone ingrowth and a higher bone mineral apposition rate in the Si-HA implanted groups (Patel et al., 2002). In another study, Silica-CaP nanocomposite scaffolds were evaluated by mechanical and cell culture tests (Gupta et al., 2007). After intense mechanical tests, Polymerase Chain Reaction (PCR) study had been done in in vitro conditions. Although the superior effect of scaffold had been observed in cell culture conditions, the scaffolds were not tested in in vivo conditions.

The ceramics of this study had HA basement. Sr, Si and BMP-2 were integrated for enhancing mechanical and biological properties of ceramics. There were several studies with especially polymer or metal-reinforced ceramic systems for improving properties. One of the purposes of this thesis was researching bioceramics, which did not contain any supportive biomaterial as metal. The main difference of HA based ceramics of this study from other researches about HA systems, was evaluating them in terms of 3
different subject: with mechanical, *in vitro* and *in vivo* tests. Mechanically strong and biocompatible bioceramics were aimed to be generated in this study.

1.10.3 Trials Related to Defect Healing in Rats:

Different kinds of materials have been applied to defects in numerous orthopaedic studies. Logically, Ca based materials were the preferred ones.

3 types of bone grafts containing different concentrations of Ca–Sr–zinc–silicate glass were evaluated by *in vitro* and *in vivo* tests with rats (Boyd et al., 2009). The grafts were applied to fibroblast cells in culture conditions. Then the grafts were implanted to the femoral defects of healthy and ovariectomized rats, which were caused by dental bur. An alternative bioglass based material Novabone® was used for comparison. The grafts performed well with new bone formation areas in the healthy rats and diminished implant response in the osteoporotic rats. All three grafts caused higher cell viability than the alternative material; Novabone. The grafts that contained higher levels of Sr than others resulted in more bone development.

Develioğlu applied HA based Unilab Surgibone® to calvarial defects of rats that had been formed by trephine (Develioğlu et al., 2005). The material did not reveal significant osteoconductive properties according to histological results. In addition, no foreign body infection was detected at the experiment sites. The grafts were accepted as biocompatible, but more research is needed to investigate their resorption properties.

Kochi applied highly porous HA-containing resins to defects in rats and evaluated using micro focus computerized tomography (Kochi et al., 2009). An increase in bone volume caused by HA was observed.

Mardas investigated the effect of HA-synthetic cell binding peptide on calvarial defects in rats (Mardas et al., 2008). Limited bone formation was detected in the treated defects and the differences between the treatment and control groups were not significant.
CaP bone cement modified with chondroitin sulphate was applied to tibial defects in rats, formed by using a drill (Schneiders et al., 2008). The chondroitin sulphate supported material had more compressive strength than the non-supported material. Bone contact with new bone formation was observed at day 28 in the treatment groups due to the chondroitin sulphate.

Mostly Ca based biomaterials had been tried for defect healing studies. The materials were evaluated by mechanical tests or in vitro tests before application and tissue tests after implantation. All three type of assessment were done in this thesis study. Because Ca based materials showed discrepancies between different researches. The results of in vitro tests were waited to support the results of in vivo tests in this study. Also mechanical test results were shown for bioceramic systems to become an alternative treatment way in the future.

1.10.4. Trials with BMP-2 for Bone Formation:

Bone morphogenetic protein (BMP) triggers bone formation in animal studies and was preferred in bone regeneration studies (Reddi AH (1994,1997), Schmitt et al. (1999)).

Numerous studies have shown the beneficial effect of BMP-2's role in bone formation in vivo (Wozney et al. (1988), Wang et al. (1990), Volek-Smith et al. (1996)) and in vitro (Katagiri et al. (1990), Chen et al. (1991), Theis et al. (1992), Rosen et al. (1994), Chaudhari et al. (1997), Yamaguchi et al. (1995,1996), Wang et al. (1993), Hay et al. (1999)). Bone morphogenetic proteins were isolated from bovine bone extracts and their stimulation effects on bone formation subcutaneously were observed in rats (Urist MR, 1965). Since BMP-2 can stimulate osteogenic differentiation of MSC (Wang et al., 1990), gene therapy with BMP-2 is an alternative in osteoporosis treatment. Recombinant human BMP-2 (rhBMP-2) caused cartilage and bone formation, applied through implantation, in rats (Wozney et al. (1988), Wang et al. (1990)). BMP-2 and -7 absorbed into collagen sponge, was applied to repair
tibial fracture in spinal fusion treatment (White et al. (2007), Jones et al. (2006), Garrison et al. (2007)). BMP-2 can also affect the absorption properties of HA scaffolds; BMP-2 integrated functionally graded apatite (fg-HA) resulted in the accelerated bioabsorption of materials (Murata et al., 2007).

BMP-2 has been combined with various materials in studies on bone formation. Poly lactic acid-co-glycolic acid (PLGA) microspheres were tried out as carriers for BMP-2 and resulted in an increase in ALP activity in a 70 day period in in vitro and in vivo studies (Kempen et al., 2008). Biodegradable gelatin hydrogel with BMP-2 has also been tried and the induction of bone formation was observed (Fukunaka et al., 2002).

BMP-2-containing apatite-coated poly D,L-lactide co glycolide/nanohydroxyapatite (PLGA/HA) particulates has been tested in in vivo conditions (Kim et al., 2008). BMP-2 carrying scaffolds caused more bone formation in the calvarial defect model when compared with fibrin gel containing BMP-2. Mineralization in the healed areas was broader in BMP-2 loaded groups than in BMP-2 deficient groups.

Inactive collagen bone matrix (ICBM-means demineralized bone matrix that was extracted with guanidine or urea to deport non collagenous proteins) has been mixed with different concentrations of rhBMP-2 and applied to calvarial defects in rats (Ron et al., 1992). Significant bone regeneration was observed in ICBM+BMP-2 applied groups.

Hirata investigated the effect of carbonate apatite-collagen sponge (in a porous HA frame ring) scaffolds on cell cultures (Hirata et al., 2007). These scaffolds were also reinforced with BMP-2 and applied to the periosteum cranii of rats. The proliferation of OBs, ALP activity in in vitro tests and bone formation in in vivo tests was observed.

A combination of MSC, HA and BMP-2 had been tested by implantation into rats (Noshi et al., 2001). Although HA and BMP-HA did not show bone formation, in particular MSC-HA-BMP combination resulted in obvious bone formation at all time points.
The time for BMP application has been evaluated with bovine HA implanted in rats (Warnke et al., 2010). Four weeks after the intramuscular insertion of HA blocks to one side of rats, a second block was again inserted to the other side of rats. rhBMP-2 was injected to both blocks during the second implantation. The delayed application of BMP-2 resulted in slightly lower bone density development.

HA and HA-TCP combination ceramics with the magnetic field have been evaluated for their effects on bone healing in \textit{in vitro} conditions. BMP-2 was then added to those ceramics and implanted subcutaneously for observation in \textit{in vivo} conditions (Wu et al., 2010). Ceramics with the magnetic field showed good biocompatibility as the stimulation of cell proliferation and new bone-like tissue formation was seen by the expression of BMP-2.

BMP-2 was evaluated in many researches by \textit{in vitro} tests and \textit{in vivo} tests. BMP-2 was applied in a biomaterial by intramuscularly or to bone defects. BMP-2 was assessed by adding into polymer, HA or collagen based biomaterials mostly. These studies lead us to use BMP-2 for enhancing properties of ceramics. The bioceramics were also containing different concentrations of Sr in this study. By this approach, the effect of BMP-2 had chance to be evaluated with different concentration of Sr in ceramics by \textit{in vitro} and \textit{in vivo} tests.

1.10.5. Trials with Sr Substituted Bioceramics:

The effect of Sr as an input to osteoid tissue development and the repression of the resorptive system in bones were initially observed by Lehnerdt (Lehnerdt F, 1910).

Sr$^{+2}$ has been used since the 1950's for bone healing (Shorr et al. (1952), McCaslin et al. (1959)). One of the first studies about the Sr effect in osteoporosis involved giving Sr lactate, which caused more Ca storage than only Ca administration (Shorr et al., 1952). Sr$^{+2}$ containing drug S12911 (di-
strontium salt of 3-(3-cyano-4-carboxymethyl-5-carboxy2-thienyl)3-azapentanedioic acid) has been tried for the treatment of osteoporosis (Marie et al., 1993) and normalization of bone mineral content has been detected after S12911 application in ovariectomized rats (Marie et al., 1993).

Commercial drugs that contain Sr ranelate have been used as a preventive treatment for osteoporosis (Meunier et al. (2002,2004), Reginster et al. (2005)). Sr ranelate regulates bone cells' CaSR activity by raising the concentration of Ca in the microenvironment (Pi et al., 2004). CaSR's signal resulted in bone formation by OBs (Tang et al. (2007), Ammann et al. (2004), Canalis et al. (1996), Baron et al. (2002), Takahashi et al. (2003)). Sr ranelate triggered an increase in bone resistance of L4 body, trabecular bone volume, trabecular thickness, cortical thickness (Ammann et al., 2004), BMD level (Roux C, 2008), and a reduction in vertebral fracture after a year (Seeman et al., 2006b). According to Ammann’s study, a high dosage Sr ranelate treatment in diet affects the bone tissue of vertebra, but lowering amount of drug intake did not give the same result (Ammann et al., 2004). Sr ranelate has been approved as a drug for osteoporosis treatment by the European Union since 2004. Outside of trials on humans, Sr ranelate also increased bone formation and decreased bone resorption in in vivo studies in rats (Marie et al. (1993, 2001), Hott et al. (2003)). Sr ranelate caused cell proliferation and collagen-noncollagen protein synthesis stimulation in rat calvarial OB cultures (Canalis et al., 1996). However, there are some disadvantages of Sr ranelate usage. Side effects of Sr ranelate as nausea, headache or diarrhea can be improved with time (Cole et al., 2008). According to reports of UK General Practice Research Database, other symptoms include memory loss, gastrointestinal disturbance, venous thromboembolism, pulmonary embolism, skin response, drug rash with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson syndrome (Grosso et al. (2008), Vestergaard et al. (2010)). Dermatitis, eczema (Roux C, 2008) and toxic epidermal necrolysis (Lee et al., 2009) were also seen at patients.
Si and Sr substituted ceramics have been researched before. The studies mostly focussed on material properties and cell culture experiments. Si substitution into HA ceramics caused earlier bone repair than only HA ceramics according to a previous in vivo study (Hing et al., 2006). Sr silicate (SrSiO$_3$) has been seen to stimulate HA formation. At day 7, SrSiO$_3$ resulted in hydroxycarbonate apatite formation by soaking simulated body fluid. Also SrSiO$_3$ had a cytocompatible effect, resulting in the proliferation of mouse fibroblast and rabbit bone marrow stromal cells (Zhang et al., 2010). Again, in another study using Ibuprofen, Sr-containing HA was shown to have drug loading and controlled release properties (Zhang et al., 2010).

Sr substituted HA coating on titanium implants was researched in ovariectomized rats by Li et al. (Li et al., 2010). After material characterization, a significant difference in Sr substitution was observed in in vivo tests. Osteointegration was evaluated by histomorphometry and microtomography analysis. The Sr containing HA coated implant had better results than only HA coated implants. Titanium mostly caused good biocompatibility in bone; and a coating with Sr was a meaningful decision for enhancing osteointegration. In the ovariectomized rat model, the effect of ceramics could have been assessed using dual-energy X-ray absorptiometry (DXA), X-ray picture (XP) and in vitro studies (such as a proliferation test). The above research has certain similarities with this current thesis, but this study also examines the behavior of Sr substituted HA, without a titanium scaffold, in a cell culture environment.

Sr containing HA cement had been applied to hip replacement model and observed for integration of composite to bone (Ni et al., 2006). An apatite layer had been observed at samples that had Sr-HA cement by spectrometry. Examination of apatite layer histomorphometrically could give more clear results.

Sr substituted β-tricalcium phosphate (β-TCP) had been evaluated for release and cytocompatibility properties (Hamdan Alkhraisat et al., 2008). The material caused same effect as not Sr containing material at human OB
culture condition. Although the release test and cytocompatibility have been assessed, the different concentrations of Sr could be compared and wide \textit{in vitro} tests could be done for observation of effect to OBs. This material could be conducted to \textit{in vivo} studies as osteoporotic models.

Sr-containing hydroxyapatite/polyetheretherketone (Sr-HA/PEEK) composites had been tried for load bearing orthopedic applications (Wong et al., 2009). The mechanical properties of human bone had been studied to be mimicked at that study. Bioactivity of Sr containing scaffold was more according to apatite formation assays. But no difference had been observed at cell culture experiments although Sr has positive effects at OBs according to other researches.

Sr containing HA bone cement had been prepared by Guo (Guo et al., 2005). Compressive strength of ceramics had been evaluated with different concentration of Sr content of samples. Although cytotoxicity test and cell culture experiments have been conducted, the composites had not been tried in \textit{in vivo} experiments.

Sr incorporation into bioactive glass had been resulted with enhancement of metabolic activity of OBs. ALP activity had been observed near decrease at Oc activity (Gentleman et al., 2010). However, Bioglass had not been preffered for fractures at especially load bearing sites.

Sr-doped CaP scaffolds had been incubated with rat OB sarcoma cells and effect of Sr had been evaluated by MTT and ALP assays (Qiu et al., 2006). Sr containing scaffolds resulted significant cell proliferation rates than that of control. The appearance of cell-scaffold contact had been examined by SEM. Porous scaffold thought to be tried for bone regeneration by researchers. When pore formation could be studied, more bone ingrowth can be resulted in this manner.

Near Sr, other elements had been added to researches about bone. Sr and Magnesium (Mg) addition to \(\beta\)-TCP have been tried (Banerjee et al., 2010). The human OB culture conditions resulted with development at cell proliferation and attachment. Also, the ceramics had been evaluated in \textit{in vivo}
conditions and higher bone formation rate had been observed. Near this, lower concentration of Ca had been detected by urine analysis of rats which had Sr contained β-TCP application.

Sr and zinc had been incorporated into Ca-Si system and had been examined with mechanical, *in vitro* and *in vivo* tests (Zreiqat et al., 2010). Induced attachment with proliferation of human bone derived cells had been observed. Effect of growth factor by addition to scaffold may be investigated in this study.

Also, according to researches, Sr addition to ceramics improved their compression strengths (Guo D (2005), Dagang G (2010), Liu WC (2010)).

Sr had been used as treatment for osteoporosis of humans since many years. The effect of Sr-Si – incorporated biomaterials was evaluated by either *in vivo* or *in vitro* tests. In some researches any significant result was obtained. The difference of this thesis study was assessment of different concentration of Sr-containing ceramics by *in vitro* and *in vivo* tests for finding most adequate ceramic constitutions. Also BMP-2 was applied to Sr-containing ceramics because of researching whether effect of BMP-2 could improve the biological properties. Mechanical properties of the ceramics may support the availability of bioceramics for defect healing in the future.

1.11. Originality:

Encouraging results have been obtained by researchers to treat bone defects in OVX rats. The difference of this study is comparison of different concentrations of Sr substituted Si-HA ceramics with BMP-2 addition by *in vitro* and *in vivo* tests. After characterization of ceramics, compression test was performed for measuring strength of materials. The Sr release from ceramics was observed by a spectrometer. Then different concentrations of Sr integrated BMP-2 added ceramics were evaluated by *in vitro* tests for cell proliferation and biocompatibility. *In vitro* tests were important to observe the effects of BMP-2 and Sr in ceramics with OBs. The moderately better Sr
concentration was then selected and assessed in \textit{in vivo} tests using XP, DEXA and micro tomography.

The tests in this study were all linked. The results of each test were analysed and sample concentrations for application to the next test were decided prior to passing on to the next test. The compression test and Sr release test initially gave data about the ceramics. The \textit{in vitro} experiments were important for obtaining the best concentration of Sr in a rat OB culture environment. The application of the ceramics to defects in an ovariectomized rat model resulted to being able to gauge the biological impact of the ceramics using a histological approach.

This research in this thesis was a multidisciplinary study that provides evidence about the effect of BMP and/or Sr-substituted Si-HA ceramics in \textit{in vitro} and \textit{in vivo} conditions after mechanical tests.

1.12. Aims of The Study:

First aim of the study was investigating mechanical characterization of Si-HA ceramics that have also Sr contents. Secondly, observation of behavior of Sr substituted HA ceramics in distilled water environment by spectrometer were undertaken. And lastly, evaluation of effect of BMP and/or Sr incorporated Si-HA ceramics in cell culture and \textit{in vivo} conditions.

\textit{Whether adding Sr into Silicon doped Hydroxyapatite ceramics will improve compression strength?}

Sr or BMP addition to Si-HA ceramics were researched with four different approaches as their effect at mechanical, chemical, cellular and histological tests. Evaluation of ceramics was done with compression test near observation them by X-ray diffraction test, scanning electron microscope (SEM) and porosity test.
Whether Sr-Si-HA ceramics will release Sr in time?

Sr containing ceramics were waited in distilled water for in time period and the observation of Sr release behavior of ceramics was done by spectrometry.

Whether Sr-Si-HA ceramics are biocompatible with rat bone marrow stem cells in in vitro conditions? Whether adding BMP-2 into the ceramics will improve in vitro biocompatibility?

BMP-2 and/or Sr-containing ceramics were incubated in cell culture environment resulted with cell proliferation, ALP assays and SEM evaluations.

Whether Sr-Si-HA ceramics promote bone defect healing when implanted into rat tibia? Whether adding BMP-2 into the ceramics will improve in vivo biocompatibility?

Investigation of ceramics was finished with applying ceramics to defect areas in ovariectomized rat models. In vivo tests had 2 stages. The procedures of both stages were same. Firstly Si-HA ceramics were applied to rats and the biocompatibility properties of them were observed for a long time (31 weeks after implantation). This period was long but beneficial for observation of behavior of Si-HA ceramics before adding Sr into them. Then, Sr substituted Si-HA ceramics had been applied to other groups for examining the effect of that trace element. Effects of ceramics were examined by DXA, XP, micro CT and histology in in vivo studies.

The ability of Sr-containing ceramics to support proliferation of rat OBs and defect healing at tibias of rats was investigated in this study. These researches were done with Sr-containing ceramics for observation of their possibility to be used for healing faster at postmenopausal women against possible osteoporotic fractures in the future.
Figure 1.3. The groups that were tested in all experiments and their evaluations by radiology, dual energy X-ray absorptiometry, micro-tomography and histology.
CHAPTER 2

MATERIALS and METHODS

2.1. Design

An interdisciplinary (Materials Engineering, Chemistry, Medicine) multi-center study conducted at Middle East Technical University, Hacettepe University Faculty of Medicine and Alberta University Department of Chemical and Materials Engineering was designed. Departments involved in this study are Metallurgical and Materials Engineering, Chemistry, Chemical and Materials Engineering, Medical Center and Histology and Embryology.

At the first stage of this study, the ceramics were developed and characterized. At the second stage of the study, Sr release was assessed. Compatibility of the bioceramics with cells in culture was evaluated at the third stage of the study and finally the bioceramics were implanted into rat tibia for in vivo biocompatibility assessment.

Independent variables of the in vivo study were groups (n=4) and time (n=2) and dependent variables were radiology, micro-computer tomography (micro-CT), BMD by DXA and histology scores.
2.2. Development of The Ceramic Systems:

2.2.1. Preparation of The Ceramic Systems:

Ceramics were developed at Middle East Technical University, Department of Metallurgical and Material Engineering Ceramic Laboratory by consultancy of Prof. Muharrem Timuçin.

Molecular formula of calcium HA is \( \text{Ca}_{10} \text{(PO}_4)_6 \text{(OH)}_2 \). HA powder was prepared by precipitation of solid precursors from aqueous solutions which included calcium phosphorus ions (Koç et al., 2004). Suspension of \( \text{Ca(OH)}_2 \) in water with phosphoric acid (\( \text{H}_3\text{PO}_4 \)) was prepared to produce the HA powders (Akao et al., 1981). \( \text{Ca(OH)}_2 \) (Merck #102047, Darmstadt, Germany) and orthophosphoric acid (\( \text{H}_3\text{PO}_4 \)- Merck #100564, Darmstadt, Germany) diluted in deionized water (0.1M) were used. The amount of materials that were used to prepare ceramics, \( \text{Ca(OH)}_2 \) and \( \text{H}_3\text{PO}_4 \) were adjusted in a manner that a molar ratio of \( \text{Ca: P} = 1.67 \) was maintained in the slurry with this reaction:

\[
10\text{Ca(OH)}_2 + 6\text{H}_3\text{PO}_4 \rightarrow \text{Ca}_{10}\text{(PO}_4)_6\text{(OH)}_2 + 18\text{H}_2\text{O}
\]

Hydroxyapatite

\( \text{Ca(OH)}_2 \) powder was first placed into a beaker and deionized water was added. The beaker was placed on a hot plate and contents were mixed for 30 minutes with the magnetic stirrer. The beaker was heated to 85°C. 0.1 M \( \text{H}_3\text{PO}_4 \) solution was added into this mixture through a burette in a drop wise manner. Then the beaker was placed into the oven (90°C) for drying the solution. The obtained powder was pressed into cylindrical tablets under 1250kgf/cm\(^2\) pressure. Pressed tablets were calcinated at 1000°C for 6 hours. Then the tablets were turned to powder form. Few amount of powder form ceramics were brought to XRD test for characterization. After getting XRD results, the procedure was continued. Powder form ceramics were put
into a box containing plastic coated Zirconium balls with ethanol. The box was left to turn for 12 hours onto machine which have rotating columns. Then, the powders were taken out and were put into an agate mortar for blending under ethyl alcohol with 3% polyethylene glycol (PEG). 5 gr ceramic powder was mixed with 2 cc polyethylene glycol and 1 cc ethanol. This mixture was waited 1 day at room temperature for drying. Tablet forms were pressed from dried mixture and sintered at 1200°C in PROTERHM (PLF 15015) sintering furnace for 4 hours. PLF 15015 sintering furnace is capable to reach 1450°C in temperature.

The procedures of Si-HA and Sr-Si-HA powder preparation had been the same as of the HA powder. Si and Sr were added to ceramics at initial part as mixing to Ca(OH)_2 containing mixture. The phosphate of HA was partially replaced by Si to produce Si-doped HA. Source of silicon dioxide (SiO_2) was Sigma Aldrich (cat.# S5130).

Sr carbonate was added to ceramics as 250, 500 and 1000ppm amounts. The formula of Sr integrated HA new ceramic was:

\[ \text{Ca}_{10-x}\text{Sr}_x(\text{PO}_4)_{6-y}(\text{SiO}_4)_y(\text{OH})_{2-y}. \]

‘x’ means Sr atoms that were integrated into the ceramic and y designates the SiO_4 content in the ceramic.

**Table 2.1.** Material weights for the preparation of the ceramics.

<table>
<thead>
<tr>
<th>Ceramics</th>
<th>Ca(OH)_2 (gr)</th>
<th>H_3PO_4 (cc)</th>
<th>SiO_2 (gr)</th>
<th>Sr (cc)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA</td>
<td>25.8</td>
<td>40.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Si-HA</td>
<td>29.6</td>
<td>46.1</td>
<td>0.7</td>
<td>-</td>
</tr>
<tr>
<td>Sr250-Si-HA</td>
<td>29.59</td>
<td>47.0</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Sr500-Si-HA</td>
<td>29.58</td>
<td>47.0</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Sr1000-Si-HA</td>
<td>29.56</td>
<td>47.0</td>
<td>0.2</td>
<td>0.4</td>
</tr>
</tbody>
</table>
2.2.2. Material Properties:

2.2.2.1. X-Ray Diffraction (XRD) Analysis:

X-ray diffraction analysis was carried out as previously described ((Hernandez et al. (2008), Li et al. (2007)). Briefly, the RIGAKU (model:D/max 2200/PC, Tokyo, Japan) instrument was used for material characterization at Middle East Technical University Department of Metallurgical and Material Engineering. The diffractometer had been operated at 40kV and 40mA and powdered samples of ceramics were scanned between 2θ values of 20 and 50°. \( \lambda \) value was 1.542 Å, step size was 0.05° with 3 sec count time in order to determine the crystal structure of each apatite.

XRD result of HA, Si-HA, Sr250-Si-HA, Sr500-Si-HA and Sr1000-Si-HA ceramics are presented in Figure 2.2. The first image in Figure 2.2 presents XRD analysis result of HA. Crystallographic description of HA ceramics was carried out according to the Joint Committee on Powder Diffraction and Standards (JCPDS, HA, 09-0432).
Figure 2.2. XRD graphs of HA, Si-HA, Sr250-Si-HA, Sr500-Si-HA, Sr1000-Si-HA ceramics.

The pattern of the HA sample synthesized in the absence of Sr displays well defined and adequate peaks in agreement with JCPDS, HA, 09-0432. Molar ratio of Ca:P was wanted to be 1.67 in HA ceramic. If more and sharp peaks at around 2θ values of 30°-40° had been seen, the ceramic was named to have CaO or TCP content. If the ceramic have CaO content the molar ratio of Ca:P will be more than 1.67. And if ceramics have TCP content, the Ca:P ratio will be decreased.
2.2.2.2. Porosity Test:

Pore formation in ceramics allows osteoblast penetration and physiological fluid permeation of whole porous apatite scaffold (Landi et al., 2003). Pore formation in the ceramics of this study was important for observation of cell ingrowth into the ceramics in the *in vitro* experiments.

Porosity test in this study can be considered close to Standard Test Method for Water Absorption, Bulk Density, Apparent Porosity, and Apparent Specific Gravity of Fired Whiteware Products (ASTM-C 373-88 (Reapproved 2006)). But xylene had been used in this study instead of water in the protocol and 1 tablet from every ceramic group was included to test. For obtaining porosity firstly, weights of ceramic tablets (*W*$_{dry}$) were measured before applying them into xylene. Ceramic tablets were immersed into xylene for 24 h. After 24 h, weight of suspended samples (*W*$_{susp}$) was measured. The ceramics were put onto paper towel for wiping out of the xylene from the surface and saturated weights (*W*$_{sat}$) were measured.

The results of the test were reached with using the formula given below:

\[
d_{\text{bulk}} = \frac{W_{\text{dry}} \times 0.861}{W_{\text{sat}} - W_{\text{susp}}}
\]

*dbulk*: percentage of ceramic form only

0.861: density of xylene

When *d*$_{\text{bulk}}$ is calculated for every ceramic, another formula had been used for obtaining material percentage and porosity percentage.

\[
d_{\text{bulk}} / d_{\text{th}} = \text{material}\% \\
1 - \text{material}\% = \text{porosity}\% \\
d_{\text{th}}: \text{is the theoretical density of HA}=3.156 \text{ g/cm}^3
\]

porosity\%: percentage of porosity in ceramics
**Table 2.2.** Bulk density (g/cm$^3$) of ceramics used in this study.

<table>
<thead>
<tr>
<th>Material</th>
<th>$d_{\text{bulk}}$ (g/cm$^3$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA</td>
<td>1.843</td>
</tr>
<tr>
<td>Si-HA</td>
<td>1.914</td>
</tr>
<tr>
<td>Sr250-Si-HA</td>
<td>1.99</td>
</tr>
<tr>
<td>Sr500-Si-HA</td>
<td>1.89</td>
</tr>
<tr>
<td>Sr1000-Si-HA</td>
<td>1.973</td>
</tr>
</tbody>
</table>

The porosity % values of the ceramics are said to be similar (Figure 2.3.). Porosity test had been done with only 1 tablet from every ceramic, so there were no standard deviation results. But the porosity values of all samples can be accepted to be close. The few differences between results might be related to sintering (Bucholz RW, 2002).

![Porosity percentages of the ceramics assessed in this study.](image)

**Figure 2.3.** Porosity percentages of the ceramics assessed in this study.
2.2.2.3. Compression Test:

The Schimadzu (Schimadzu Corporation, model AGS-J, max 10kN application capacity, Tokyo, Japan) mechanical testing machine and its Trapezium data processing software were used to measure the compression strength of the ceramics.

![Schimadzu mechanical testing machine](image)

**Figure 2.4.** Schimadzu mechanical testing machine.

Cylindrical ceramic tablets (diameter: 9.4-9.8 mm and height: 7.7.2 mm in size) were placed in the machine and axial compression load was applied onto the tablets. The load to failure of the tablets was recorded and the strength was calculated. Four ceramic tablets from every ceramic group were included to this test.

\[
\sigma = \frac{F}{A}
\]

is the formula that the calculation of the compression strength “σ” was made. “F” means the load to failure, and “A” is the area of circle, which is the upper part of the cylinder.
2.2.2.4. Scanning Electron Microscopy:

The JSM-6400 scanning electron microscope (JEOL, Tokyo, Japan) equipped with the NORAN System 6 X-Ray microanalysis system was used at the Middle East Technical University, Department of Metallurgical and Material Engineering. SEM examinations were performed on broken surfaces. Tablets were coated with a gold layer by the sputter coating equipment and SEM pictures were obtained.

Sr-Si-HA nanocrystals display more perturbed shapes than Si-HA nanocrystals according to Figure 2.5. The surface of Si-HA sample seemed to be more regular.

![SEM images](image)

**Figure 2.5.** SEM images (a, b, c, d) of the Si-HA, the Sr250-Si-HA, the Sr500-Si-HA and the Sr1000-Si-HA ceramics.

2.3. Sr Release Test:

The experiments had two stages. Firstly a ceramic was immersed in an experiment box with 20 ml distilled water and assessed for 3 and 14 days in
room temperature. At the second stage, a ceramic was immersed in 20 ml serum and assessed for 3 and 14 days in 37°C, 5% CO₂ environment.

Ceramics that were incubated in distilled water or serum were:

a) HA  
b) Si-HA  
c) Sr250-Si-HA  
d) Sr500-Si-HA  
e) Sr1000-Si-HA

Samples were analysed at 421 nm wavelength using the inductively coupled plasma optical emission spectrometry (Profile Plus ICP-OES, Teledyne Leeman Labs, Hudson, USA) at the Middle East Technical University Department of Chemistry. Software of spectrofotometer is WinICP Database 1,3.

![LEEMAN-ICP-OES spectrometry and software.](image)

Figure 2.6. LEEMAN-ICP-OES spectrometry and software.

Software has been used for visioning analysis results. A calibration plot in a range of 10 ppm – 0.005 ppm was obtained with Sr (1000 µg/ml, Aldrich, Milwaukee, USA) stock solution. When R² value reached 0.99, then all samples were analyzed for their Sr amount. Samples were diluted at 1/3 ratio because of their intense environments.
2.4. *In Vitro* Experiments:

Sr-containing Si-HA ceramics were used in cell cultures for finding the ideal ceramic systems with the ideal Sr ratio after their sterilization in autoclave at 132°C for 45 min. *In vitro* experiments determined cell proliferation by MTT assay, DNA assay, ALP tests and SEM observations.

Cell culture tests and BMP absorption into the ceramics were performed at University of Alberta Department of Chemical and Materials Engineering by the consultancy of Prof. Hasan Uludağ.

6 study groups were established for the cell culture experiments.

i- HA  
ii- Si-HA  
iii- Sr250-Si-HA  
iv- Sr500-Si-HA  
v- Sr1000-Si-HA  
vi- Control (cell+media)

These groups were tested with and without BMP addition to the environment.

Bone marrow stromal cells were obtained from Sprague Dawley rats. Rats were terminated by CO₂ inhalation and placed in a beaker with 70% ethanol for 10 minutes for surface sterilization. The bone marrow was isolated after the separation of the skin and surrounding soft tissues.

Bones were carefully removed and placed in a 50 ml tube containing sterile Hanks’ Balanced Salt Solution (HBSS-Bio Whittaker®, cat. 10-527F). Epiphyses of bones were cut off by using the Littauer bone cutter. The marrow was eluted with the Dulbecco’s Modified Eagle Medium (GIBCO®, cat.11995-065) supplemented with 10% heat inactivated fetal bovine serum (FBS: GIBCO®, cat. 26140-079), Penicillin/Streptomycin (GIBCO®, cat.15140-
and ascorbic acid (Sigma-Aldrich, cat. A-4544, St. Louis, USA). The same medium had been also used for cells to express osteoblast phenotype.

Cells were centrifuged for 6 minutes at 600 rpm. Supernatant was removed and cells were re-suspended in 10 ml media and plated in T-25 cm² flasks (~10 mL culture medium into each). Cells were grown in culture media with 10% FBS.

When cells were grown to ~80% confluence, the medium were vacuumed out from T-25 cm² flask; 5 ml of HBSS was added to the flask for cell washing that stayed for 30 s-1min. When HBSS was vacuumed out of the vials, 1ml of Trypsin (Sigma, T4174, St Luis, USA) was applied to the flask for 3 minutes with swirling to dissociate the cells. Cell detachment was observed under the inverted microscope. 5 ml medium was added to the flask and the mixture was collected to a test tube, then centrifuged for 6 minutes at 600 rpm. Supernatant was vacuumed out without touching to cells that were settled at the bottom. Medium had been added to test tube and cell count was conducted using a hemocytometer.

Cells were distributed into 24 well cell culture plates (Falcon by Becton Dickinson, NJ, USA) at amount of 20 µl/well with 500 µl of basic media. Cells were cultured in humid atmosphere containing 5% CO₂ at 37°C. Media was changed twice a week. All cell culture experiments were conducted as duplicate.

The BMP-2 was provided by Dr Walter Sebald from University of Wurzburg, Germany. 200ng/ml rhBMP-2 had been preferred for application to every ceramic in 24 well cell culture plate. Totally 12 µg BMP was added into 1200 µl RNase free water (Invitrogen, New York, USA). 20 µl from mixture (amount of rhBMP-2=200ng/ml/well) was applied into every well that was containing 0.5 ml basic medium.
2.4.1. Tests and Microscope Observation for *In Vitro* Experiments:

2.4.1.1. MTT Test:

MTT test had been preferred by many researchers for observation of cell proliferation rate (Wu et al., 2010).

Different amount of cell suspensions were applied onto the 24 well-plates that contained 0.5 ml basic medium for an MTT calibration curve. The cells were allowed to attach and grow and the basic medium was changed every 4 days.

The MTT test has been used also for cells that were grown on ceramics. These cells were incubated with or without BMP and the assay was performed at days 1, 6, and 12. Content of the ceramic applied cultures was 20 µl of cells and 500 µl of media.

The MTT (3-(4,5-dimethylythiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used for measuring cell viability. MTT solution was prepared with Thiazolyl Blue Tetra-zolium Bromide (Sigma-Aldrich, catalog number M2128-1G, Oakville, Canada) and HBSS at 5 mg/ml. After filtration of this solution, 100 µl MTT solution was added onto the cells of MTT calibration assay and ceramic applied cultures at stated days. Multi well plates were put into 37°C and 5% CO\textsubscript{2} incubators for 2 hour. Then supernatant was taken out and 1 ml dimethylsulfoxide (DMSO-(GIBCO-Invitrogen cat.11101-011, Ontario, Canada)) was added into multi well plates. The dissolved samples were transferred into 96 well plates (Corning, New York, USA) at 200 µl/well and absorbance was quantified at 570 nm (Issa Y, 2008) by using the KCjunior™ software(Bio-Tek Instruments, Winooski, USA) in a spectrofotometer (ELx800, BIO-TEK Instruments Inc., Winooski, Vermont, USA).
2.4.1.2. ALP Test:

Typical cytochemical markers of osteoblast differentiation are ALP and mineralized bone nodules (Zamunovic et al., 2004).

ALP tests were made with cells in culture that were prepared for ceramic effect observation. Medium from the wells had been removed and wells were washed with 1 ml HBSS. ALP buffer (0.5 M 2-amino-2 methylpropan-1-ol, 0.1% (v/v) Triton x-100 in distilled water; pH:10.1) was added after removal of HBSS to lyse the cells. The cultures were incubated for 2 hours. 10 mg p-nitrophenyl phosphate (Sigma-Aldrich, catalog number P4744-5G, Oakville, Canada) was dissolved in 5 ml ALP buffer to give 2 mg/mL solution.

50 µl of lyzed cell solution were transferred from culture wells to a new 96 well plate and 50 µl from p-nitrophenyl phosphate solution was added onto them. Kinetic changes in absorbance were quantified at 570 nm by using the KCjunior™ software in a spectrophotometer (Mostafa et al., 2009).

2.4.1.3. DNA Test:

CyQUANT® Cell Proliferation Assay Kit (Invitrogen-Molecular Probes; catalog number C7026, Eugene, Oregon) was used for this aim. The kit contained cell lysis buffer, dye and DNA. Firstly lysis buffer had been
prepared with CyQUANT cell lysis buffer and RNAse free water according to the manufacturer's instructions. 2 ml of solution had been included to calibration study and 18 ml was used later. 6 eppendorf tubes and DNA (10 mg/ml) were used for initial experiment.

![Diagram showing steps of sample preparation.]

**Figure 2.8.** Preparation of standard curve samples for the DNA assay.

50 µl from samples and tubes of calibration were put into 96 well plates as duplicate study. Whole content of the dye was mixed to initial 18 ml (lysis buffer+RNAse free water) solution and 50 µl from this solution was added onto all samples in a 96 well-plate. After dye application, 485-527 nm absorbance was run in Fluroskan Ascent Microplate Fluorometer (Fluroskan Ascent Thermo LabSystems, Helsinki, Finland) and results were followed by using the Ascent software (Varkey et al., 2007).

**Figure 2.9.** Fluroskan Ascent Microplate Fluorometer and Ascent software.
2.4.1.4. SEM Observation:

After proliferation tests, ceramics were used for SEM observation. Contents of the well that contained cells incubated with ceramics were taken out and rinsed with 1 ml HBSS. 0.5 ml 3% glutaraldehyde in HBSS was added to every well and incubated for 24h. When glutaraldehyde has been removed; 1 ml of 50%, 60%, 70%, 80%, 90% and 100% ethanol was added for each period of dehydration of the samples (Douglas et al., 2010). After incubation with different concentrations of ethanol, the plates were incubated at +4°C until observation. Ceramic tablets were observed with SEM at Alberta University.

2.5. In Vivo Experiments:

Ceramics were used alone or combined with growth factors for bone repair (Nunes et al., 1997).

Ceramics that were prepared at Middle East Technical University Department of Metallurgical and Material Engineering were applied to 36 week old female Sprague Dawley rats (range of weight 225-250g) at Hacettepe University Surgical Research Laboratory and housed at 12 h light/dark cycle with room temperature set at 25°C. Rats had adlib food and water. Ethical commission permission (#2007/32) was obtained on March 26, 2007. Housing, animal environment and experimental procedures were approved by the Hacettepe University Experimental Animal Care and Use Committee.

Rats were randomly assigned into experimental groups:
a) HA= rats that had OVX, defect operation and HA ceramic applied to defects.
b) Si-HA= rats that had OVX, defect operation and Si-HA ceramic applied to defects.
c) Sr-Si-HA= rats that had OVX, defect operation and Sr1000ppm-Si-HA ceramic applied to defects.
d) BMP-Si-HA= rats that had OVX, defect operation and BMP-Si-HA composite applied to defects.
e) Sr-BMP-Si-HA= rats that had OVX, defect operation and Sr1000ppm-BMP-Si-HA composite applied to defects.
f) Control= rats that had OVX, defect operation and ceramic was not applied to defects.
g) Control 2= rats that did not have OVX, defect operation or ceramic application operation.

After *in vitro* studies, ceramics were turned to powder form and autoclaved, then sterile rhBMP-2 had been applied to them without effecting from autoclave negatively. Two microgram of rh-BMP-2 was dissolved in 8 µl of injectable sterile water (Carlo Erba, Rodano, Italy), applied to ceramics and dried for 2 hours in room temperature and stayed for 4 days at -20°C (Noshi et al., 2001). Powder form of ceramics was applied to bone defects easily as other studies that used granule type ceramics (Gonda et al., 2009).

2.5.1. Ovariectomy Operation:

Quantity and quality of fracture callus is decreased during early period of fracture healing in OVX rats, so osteoporosis inhibits bone formation and mineralization (Xu et al., 2002). OVX caused osteoporosis results with low rate of fracture healing (Walsh et al., 1997).

Bone mineral densities (BMD) by DXA (DPX-L Lunar Radiation, USA) and XP (Siemens Multix C, Erlangen, Germany) measurements were done at the Middle East Technical University Medical Centre. Measurements were done before OVX, defect operations and continued 2 week and 4 week after defect operations. Analysis of data was done with regions of interest (ROI) at DXA machine. ROI of right tibia, left tibia, right femur, left femur and vertebra were analyzed at every measurement with DXA.
Anteroposterior radiographs were obtained on Agfa Mamoray MR3-II (Belgium) films. The distance of the x-ray source to the bones was 100 cm. The setting of the machine was 42 kV and 3.2 mA per second. Films were developed using the Ecomat 21 (ELK Medical Products, Tokyo, Japan) automatic developing machine. Radiographs were evaluated by two independent observers (MB, HK) who were blinded to the groups. They scored the radiographs for periosteal reaction, quality of bone union, bone remodeling and ceramic integration according to a scoring system modified from An (An et al., 1999). Briefly, the score range of periosteal reaction was between 0 for none and 3 for full, the score range for quality of bone union was between 0 for nonunion and 3 for union, the score range for bone remodeling was between 0 for no remodeling and 3 for full remodeling cortex, and the score range for implant integration was between 0 for no change to 3 for fully replacement. The lowest and highest possible scores were 0 and 12, respectively.

**Figure 2.10.** XP images of rats.

The groups of *in vivo* study had 2 stages as explained before. Firstly only Si-HA group had been compared with control (defect only) group. The XP values of these groups belong to only before OVX and operation time. This type of analysis helps us to see whether there is deformation before implantation.
The second stage of study was done with other ceramic groups and healthy group. The XP results of these second stage groups were evaluated at operation, operation+2week and operation+4week periods.

Figure 2.11. DXA machine and appearance of results during measurement.

Initially, OVX was applied to healthy rats that had normal BMD, under general anesthesia with Alfamine 10% (contains 100mg/ml Ketamin HCl) and Alfazyne 2% (has 20mg/ml Xylazin(HCl)- Alfasan International B.V., Netherlands). Alfamine (40-60cc intramuscularly) and Alfazyne (5-10cc intraperitoneally) had been applied for anesthesia. Bilateral incisions were made via the abdominal midline incision and 2 ovaries were ligated from their suspensory ligament and veins.

Figure 2.12. The uterus and ligation of the ovaries

After closing the incision with sutures (Silk suture (Noncapillary (3/0 R. cut. edge, autotraumatic, nonabsorbable), Boz, Turkey)), spray film (OpSite® spray moisture vapor permeable spray dressing-Smith&Nephew Medical Ltd.
Hull, England) was applied onto the operation site for prevention of bacterial contamination.

2.5.2. Defect Formation:

Rats that had reduced BMD were included into the experiment according to DXA measurement results. Defects were formed in the left and right proximal parts of tibias of the rats. After anesthesia (same anesthetics for OVX operation) longitudinal incision were done from anteromedial site at tibia of rats. The defect was created at the medial cortex of the exposed tibia using a 2.5 mm drill (Dremel® 10.8 V, Lithium-ion, Breda-Netherlands). When the defect areas were cleaned with isotonic sodium clorur, cavities were filled with different type of powder form bioceramics.

![Figure 2.13](image)

**Figure 2.13.** Formation of cortical cavity and filling with bioceramics.

Powder form HA, Si-HA and BMP and/or Sr-containing Si-HA ceramics were applied to the cavities. Muscles and skin were closed and Opsite® spray was applied for asepsis.

2.5.3. After Defect Formation:

Rats were allowed free cage activity at 12 hour light and 12 hour darkness with food-water *ad libidum* until they were terminated. BMD, XP
measurements were repeated 2 and 4 weeks after defect operation. Rats were terminated by application of high amount of Alfazyne-Alfamine at 2 and 4 weeks. The tibia samples were put into Formaldehyde.

2.5.4. Tests and Measurements for In Vivo Experiments:

After termination, histological tests were done in Hacettepe University Faculty of Medicine Department of Histology-Embryology and observation of defect healing was done by micro CT in Department of Anatomy.

2.5.4.1. Micro CT:

Samples of in vivo experiments were evaluated for observation of cavities with X-ray microtomography at Hacettepe University Faculty of Medicine Department of Anatomy. Compact X-ray microtomography (SkyScan 1174, Kontich, Belgium) had been used for this purpose. X-ray tomography system allowed measuring three dimensional object structures with resolution of less than 10 μm. This system uses Windows environment, the final images can be saved in BMP or TIFF formats. After termination, bone samples in formaldehyde were brought to tomography and placed to machine with focusing defect areas. Tomography was set for voltage and current to 50 kV and 800 μA with 2.000° rotation step. After measurement, analysis was done with its software. Firstly ROI areas were drawn at the defect areas and software separates HA and bone at defect areas by different colors. Lastly the percentage of bone healing was calculated as the ratio of bone volume to tissue volume.
2.5.4.2. Histology and Histomorphometry:

Tibial bones were fixed in 10 % neutral buffered formalin at room temperature and all of the specimens sent to micro CT analysis. After analysis, all specimens were decalcified in De Castro solution (chloral hydrate, nitric acid, distilled water) and embedded in paraffin by using an automated tissue processor with vacuum.

**Figure 2.14.** Micro CT measurements.

**Figure 2.15.** Samples in DeCastro solution.

**Figure 2.16.** Semi-enclosed Benchtop Tissue Processor and Modular Tissue Embedding Center.
Figure 2.17. Samples had been embedded with paraffin.

3 µm thick sections were stained with hematoxylin & eosin (HE), Masson’s trichrome (MT). MT produces high contrast images with red bone, green osteoid-collagen and purple cell cytoplasm.

Figure 2.18. Sliding microtome that was utilized for taking sections from samples (Samples were collected by microscope slides).

Histomorphometry or quantitative histology is the analysis of histological sections by using bone formation and bone structure parameters. Photomictographs of each defect area were generated by a light microscope (Leica DMR) attached computerized digital camera (Model DFC 480, Leica, Westlar, Germany). Bright-field images of the defect area were captured and analyzed quantitatively by image processing program (Qwin Plus and LAS, Leica Inc., Westlar, Germany). Number of pixels corresponding to new trabecular bone area in each image of defect area was quantified, divided by the total number of pixels corresponding to total defect area and converted to µm² in each specimen. The cortical bone thickness was measured within
the defect zone and at the opposite healthy cortical bone site at randomly selected high power fields. The average defect zone cortical bone thickness relative to the normal cortical bone thickness was calculated and are reported as average for each sample. The tissue response to the bioceramics was semiquantitatively evaluated. (Table 2.3, Lu et al. (2004), An et al. (1999)).
Table 2.3. Histological scoring system for the tissue response.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibrous connective tissue formation</td>
<td>4</td>
</tr>
<tr>
<td>Severe disruption of dense collagenous</td>
<td></td>
</tr>
<tr>
<td>connective tissue around implant.</td>
<td>3</td>
</tr>
<tr>
<td>Disruption of normal tissue architecture and presence of moderately dense fibrous connective tissue</td>
<td>2</td>
</tr>
<tr>
<td>Presence of moderate connective tissue</td>
<td>1</td>
</tr>
<tr>
<td>Presence of delicate spindle shaped cells or mild fibroplasia</td>
<td>0</td>
</tr>
<tr>
<td>No difference from normal control tissue, no presence of connective tissue at or around implant site</td>
<td></td>
</tr>
<tr>
<td>Inflammatory cellular infiltration</td>
<td>4</td>
</tr>
<tr>
<td>Severe cellular infiltrate response to implant or tissue necrosis at or around the site</td>
<td>3</td>
</tr>
<tr>
<td>Presence of large numbers of lymphocytes, macrophages and foreign body giant cells, also notable presence of eosinophils and neutrophils</td>
<td>2</td>
</tr>
<tr>
<td>For presence of several lymphocytes, macrophages with a few foreign body giant cells and a small foci of neutrophils</td>
<td>1</td>
</tr>
<tr>
<td>Presence of a few lymphocytes or macrophages, no presence of foreign body giant cells, eosinophil or neutrophils</td>
<td>0</td>
</tr>
<tr>
<td>No difference from normal control tissue, no presence of macrophages, foreign body cells, lymphocytes, eosinophils or neutrophils at or around implant site</td>
<td></td>
</tr>
</tbody>
</table>

2.6. Statistics:

Differences between groups were analyzed by nonparametric tests Kruskal-Wallis and Dunns test. Kruskal-Wallis test shows whether there are differences between groups. Dunns test defines which groups are significantly different from other groups. These statistical tests were performed to results of in vitro, micro CT and histology tests. The samples that had those measurements were independent between each other. But for
measuring DXA and XP, same samples had been used. Because of the dependence of samples, for DXA and XP results Friedman, Mann Whitney U and Wilcoxon statistical tests were used. The groups which have p values that were equal and lower than 0.05 were accepted to be different significantly.
CHAPTER 3

RESULTS

3.1. Ceramic Properties

3.1.1. Compression Test:

There were significant differences between compressive strength values of the ceramics used in this study. The HA group resulted with lower compression strength and the value of that group was significantly (p=0.007) lower than that of the other ceramics (Table 3.1., Figure 3.1.). Although Sr500-Si-HA ceramic had lower strength than the other ceramics that contained Sr, Sr1000-Si-HA resulted with the highest compressive strength in this study. The difference of Sr500-Si-HA ceramic from Sr250-Si-HA and Sr-1000-Si-HA were significantly lower (p=0.007).

Table 3.1. Compressive strength (MPa) (Ave±SD (Range: Min-Max)) of ceramics assessed in this study

<table>
<thead>
<tr>
<th></th>
<th>strength(MPa)(Ave±SD (Range: Min-Max))</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA</td>
<td>6.98±1.27 (5.69-8.64)</td>
</tr>
<tr>
<td>Si-HA</td>
<td>101.44±20.18 (81.46-129.91)</td>
</tr>
<tr>
<td>Sr250-Si-HA</td>
<td>108.26±20.18 (81.92-128.37)</td>
</tr>
<tr>
<td>Sr500-Si-HA</td>
<td>75.77±15.14 (62.40-91.88)</td>
</tr>
<tr>
<td>Sr1000-Si-HA</td>
<td>117.51±12.39 (99.38-126.49)</td>
</tr>
</tbody>
</table>
Figure 3.1. Compressive strength (MPa) of ceramics assessed in this study.

3.2. Sr Release Test:

Sr500-Si-HA ceramic released the highest amount of Sr into distilled water on day 3. Sr1000-Si-HA and Sr250-Si-HA followed Sr500-Si-HA by means of Sr release into distilled water at the same time point. Rate of Sr release on day 14 was similar to that of day 3.
Figure 3.2. Sr release (mg/kg) from ceramics that were incubated in distilled water for 3 and 14 days (n=1 in all groups).

Sr250-Si-HA and Sr1000-Si-HA had more consistent Sr releases than Sr500-Si-HA. Especially at day 14, higher release from Sr500-Si-HA ceramic can be seen clearly (Table 3.2.).

Table 3.2. Sr amount (mg) released from the ceramics into 20 ml distilled water(data was calculated by using results of spectrometry).

<table>
<thead>
<tr>
<th>Sr content(mg)</th>
<th>Released Sr amount(mg)</th>
<th>Release %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>day 3</td>
<td>day 14</td>
</tr>
<tr>
<td>Sr250-Si-HA</td>
<td>0.05</td>
<td>16x10^{-5}</td>
</tr>
<tr>
<td>Sr500-Si-HA</td>
<td>0.1</td>
<td>54x10^{-5}</td>
</tr>
<tr>
<td>Sr1000-Si-HA</td>
<td>0.2</td>
<td>42x10^{-5}</td>
</tr>
</tbody>
</table>

Sr amount released into human serum was lower than the detection limit(15x10^{-4} mg/kg) of the spectrophotometer.
3.3. *In Vitro* Tests:

3.3.1. Proliferation Test by MTT:

MTT test showed proliferation of cells and biocompatibility of the ceramics and composites. MTT absorbance increased when the number of cells increased at the calibration test of the MTT assay (Figure 3.3).

![MTT calibration](image)

**Figure 3.3.** MTT calibration revealed increasing number of cells.

MTT assay results increased from day 1 to 6 in all groups but not in the Sr1000-Si-HA group (Figure 3.4). There were significant differences in between groups when they were evaluated among different time points. Cell proliferation rates increased in the Si-HA and the Sr250-Si-HA groups between days 1 and 6 (p<0.001). The cell proliferation rate of the Sr1000-Si-HA group however decreased between the same time points (p<0.001). At day 12, cell proliferation rates decreased in all groups.

On day 1, MTT absorbance of the Sr1000-Si-HA group was significantly higher (p=0.035) than all the other groups. On day 6, the Sr250-Si-HA group presented the highest MTT absorbance, which was
significantly (p=0.042) different from the other groups. On day 12, there was no significant difference between the MTT absorbance of the groups.

Figure 3.4. MTT assay results (a.u.) of cells that were applied to the ceramics.

When BMP was added to the ceramics, MTT absorbance decreased significantly between days 1 and 12 (Figure 3.5.). BMP-HA (p=0.006) and BMP-Sr1000-SiHA (p=0.05) presented significant MTT absorbance decrease between days 1 and 12. BMP-Si-HA and BMP-Sr250-SiHA groups MTT absorbance on the other hand increased (p=0.05) between days 1 and 6.

On day 1, the BMP-Sr500-SiHA group caused lower (p=0.035) MTT absorbance than that of the BMP-HA and the BMP-Sr1000-Si-HA groups. The results of the BMP containing ceramics had similarities with the not BMP-containing ceramics. Sr500-Si-HA still caused cells to have lower MTT absorbance on day 6. BMP-Si-HA and BMP-Sr250-Si-HA composites resulted with higher MTT absorbance on day 6 and their effects were significantly different from that of the BMP-Sr500-Si-HA composite (p=0.042). The BMP-
Si-HA composite resulted with higher ($p=0.035$) MTT absorbance than that of the BMP-HA and the BMP-Sr1000-Si-HA composites at the same time point. MTT absorbance of cells of the BMP containing ceramics reduced on day 12. BMP-HA and BMP-Sr1000-Si-HA composites resulted with significantly lower ($p=0.006$) MTT absorbance than BMP-Si-HA, BMP-Sr250-Si-HA groups.

![Figure 3.5. MTT assay results (a.u.) of cells that were incubated with BMP containing ceramics.](image)

On day 1, the Si-HA group resulted with significantly lower ($p=0.035$) MTT absorbance values than the BMP-Sr1000-Si-HA group. The BMP-Sr500-Si-HA group showed lower ($p=0.035$) results than the Sr1000-Si-HA group at the same time point. On day 6 however, the Sr1000-Si-HA group caused significantly lower ($p=0.042$) results than the BMP-Si-HA and the BMP-Sr250-Si-HA groups. On day 12, the BMP-HA group had lower ($p=0.006$) MTT
absorbance than the HA and the Si-HA groups. Significantly lower (p=0.006) MTT absorbance value was obtained in the BMP-Sr1000-Si-HA group than the HA group on the same day.

The proliferation ability of cells that were incubated with the ceramics and composites was lower than the tissue culture polystyrene (tpps) containing wells (results were not shown in graphs).

Cell accumulation on the Sr1000-Si-HA and the BMP containing ceramics were observed on day 1.

**Day 1**

![Figure 3.6. Photos of ceramics in wells before MTT test at day 1.](image)

**Figure 3.6.** Photos of ceramics in wells before MTT test at day 1.
Cells grew well in all groups with BMP on day 6. The well that contained only cells had more cells than the well containing BMP. This result was also observed at the MTT assay.

**Day 6**

![Figure 3.7. Photos of ceramics in wells before MTT test at day 6.](image)

**Figure 3.7.** Photos of ceramics in wells before MTT test at day 6.
Wells that were containing the Sr1000-Si-HA, the BMP-Si-HA and the BMP-Sr250-Si-HA ceramics had more cell accumulation than the other wells on day 12.

**Day 12:**

![Image of wells containing different ceramics](image)

<table>
<thead>
<tr>
<th>HA</th>
<th>Si-HA</th>
<th>Sr250-Si-HA</th>
<th>Sr500-Si-HA</th>
<th>Sr1000-Si-HA</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMP-HA</td>
<td>BMP-Si-HA</td>
<td>BMP-Sr250-Si-HA</td>
<td>BMP-Sr500-Si-HA</td>
<td>BMP-Sr1000-Si-HA</td>
</tr>
</tbody>
</table>

**Figure 3.8.** Ceramics in wells before the MTT test on day 12.
3.3.2. ALP Tests:

The ALP absorbance difference between days 2 and 6 in the HA group was significant (p=0.019) (Figure 3.9). ALP activity of the cells that were incubated with the Si-HA ceramics significantly (p=0.037) decreased from day 6 to 12. In the Sr250-Si-HA applied cells, ALP activity was decreased between day 2 and 12 (p=0.019). Likewise, difference had been detected at the same time points with the Sr500-Si-HA ceramics (p=0.02). Sr1000-Si-HA ceramics resulted with significant increased (p=0.037) ALP absorbance between days 6 and 12. On day 2, there were significant (p=0.035) differences between the Sr1000-Si-HA, the HA and the Sr500-Si-HA ceramics. Sr1000-Si-HA ceramics presented significantly higher (p<0.001) ALP activity than the other ceramics on day 12.

![Figure 3.9. ALP assay results (a.u.) of ceramics.](image-url)
ALP activities of the cells that were combined with the BMP-Sr containing groups reduced with time (Figure 3.10.). The ALP absorbance result of the BMP-HA group was increased between days 6 and 12 (p=0.02). Likewise, significant difference at the same time points had been detected with the BMP-Si-HA composites (p=0.032).

On day 2, the BMP-Sr1000-Si-HA group showed higher (p<0.001) ALP absorbance than the BMP-HA and the BMP-Si-HA groups. On day 6, ALP absorbance of the BMP-Sr500-Si-HA group was significantly lower (p<0.001) than the other BMP-containing ceramics. ALP absorbance of the BMP-HA and the BMP-Si-HA groups were also different (p<0.001) at the same time point. On day 12, only the BMP-Sr500-Si-HA group showed significant lower (p<0.001) results than the BMP-HA and the BMP-Sr250-Si-HA groups.

**Figure 3.10.** ALP assay results (a.u.) of BMP containing ceramics.
The ALP absorbance results of the BMP containing and not containing ceramics were compared. On day 2 there were no significant differences between the groups. On day 6, the BMP-Sr500-Si-HA group resulted with significantly lower (p<0.001) absorbance than the HA and the Sr250-Si-HA groups. The Sr500-Si-HA, which was not containing BMP, showed significantly lower (p<0.001) absorbance than the BMP-Sr250-Si-HA and the BMP-Sr1000-Si-HA groups. Near these results, BMP-Si-HA showed higher absorbance (p<0.001) than the Si-HA, the Sr500-Si-HA and the Sr1000-Si-HA groups. On day 12, ALP absorbance increased in the BMP containing groups. BMP-containing HA group caused higher (p<0.001) ALP absorbance than the Si-HA, the Sr250-Si-HA and the Sr500-Si-HA groups. The Si-HA group also showed lower absorbance (p<0.001) than the BMP-Sr250-Si-HA group. The Sr500-Si-HA group presented lower absorbance values (p<0.001) than the BMP-Si-HA, the BMP-Sr250-Si-HA and the BMP-Sr1000-Si-HA groups. The BMP-Sr500-Si-HA group however had lower absorbance values (p<0.001) than the Sr1000-Si-HA group.

On day 6 and 12, the cells that were incubated with the tcps showed higher (p<0.001) ALP absorbance than the cells that were applied with the ceramics and composites (results of tcps were not shown in graphs).

3.3.3. DNA Tests:

DNA absorbance increased when the number of cells increased at the calibration test of the DNA test (Figure 3.11).
Figure 3.11. Standard curve of the DNA assay.

The difference of DNA amounts between day 2-6 and 2-12 in the HA group was significant (p=0.024) (Figure 3.12). DNA amounts of the cells that were applied together with the Sr250-Si-HA ceramics increased from day 2 to 6 (p=0.01). Likewise, difference had been seen at the cells that were incubated with the Sr500-Si-HA ceramics (p=0.012). In the Sr1000-Si-HA group, DNA amounts increased from day 6 to 12 (p=0.026).

On day 2, the Sr250-Si-HA and the Sr500-Si-HA groups had lower DNA amount than the other groups (p=0.035). On day 12, DNA amount of the Sr1000-Si-HA group was significantly higher from the cells that were incubated with the HA, the Sr250-Si-HA and the Sr500-Si-HA ceramics (p<0.001). Cells that were grown only on tcps showed higher (p<0.001) DNA amounts than the other ceramics on day 12.
Figure 3.12. DNA assay results (µg/tablet) of the ceramics.

The DNA amount of the BMP-HA group was different (p=0.023) between days 2-6 and 6-12 (Figure 3.13.). Significant decrease in DNA amounts (p=0.012) at the BMP-Sr250-Si-HA group was observed between days 2 and 12. DNA amount difference (p=0.018) at the BMP-Sr500-Si-HA was detected between days 2-6 and 2-12. Significant decrease (p=0.018) in DNA amount at the BMP-Sr1000-Si-HA group was observed between days 2-12 and 6-12.

On day 2, the BMP-Sr500-Si-HA composite caused lower (p<0.001) DNA amount from that of the other composites. The BMP-Si-HA group resulted with higher (p=0.002) DNA amount on day 6 from that of the BMP-HA and the BMP-Sr1000-Si-HA groups. On day 12, the BMP-HA group caused higher DNA amounts than the other groups. The BMP-HA group had significantly higher (p=0.006) DNA amount results than the BMP-Sr250-Si-HA and the BMP-Sr1000-Si-HA groups. The BMP-Sr1000-Si-HA group presented
the lowest absorbance rate \( (p=0.035) \) from that of the BMP-Si-HA, the BMP-Sr250-Si-HA and BMP-Sr500-Si-HA groups.

Cells that were grown on tcps showed higher DNA assay results compared to the composites on day 2.

![Figure 3.13](image-url)

**Figure 3.13.** DNA assay results (µg/tablet) of the BMP containing ceramics.

BMP containing and not containing groups were compared by using the DNA assay results. On day 2, the HA, the Si-HA and the Sr1000-Si-HA groups had higher DNA amount \( (p<0.001) \) than the BMP-Sr500-Si-HA group. However, the Sr250-Si-HA group resulted with significantly lower \( (p<0.001) \) DNA amount than the BMP-HA, the BMP-Si-HA and the BMP-Sr250-Si-HA groups. Likewise, the Sr500-Si-HA group had lower \( (p<0.001) \) DNA amount than the BMP-HA, the BMP-Si-HA, the BMP-Sr250-Si-HA and the BMP-Sr1000-Si-HA groups. On day 6, the BMP-Sr250-Si-HA group caused higher \( (p=0.002) \) DNA amount than the HA and the Si-HA groups. Likewise, the
BMP containing Si-HA group had higher (p=0.002) DNA amount than the HA, the Si-HA, the Sr1000-Si-HA and the BMP-Sr1000-Si-HA groups. On day 12, the HA group caused lower (p<0.001) DNA amount than the BMP-HA, the BMP-Si-HA and the BMP-Sr500-Si-HA groups. The BMP-HA group had higher (p<0.001) DNA amounts than the Sr250-Si-HA and the Sr500-Si-HA groups. However, the Sr1000-Si-HA group showed higher (p<0.001) DNA amount than the BMP-Sr250-Si-HA, the Sr500-Si-HA and the BMP-Sr1000-Si-HA groups.

3.3.4. ALP/DNA Ratio:

The ALP/DNA ratio was significantly different (p=0.02) between days 2-6 and 6-12 in the HA group (Figure 3.14.), Similar differences was detected in the Sr250-Si-HA (p=0.02) and the Sr500-Si-HA (p=0.02) groups at same time points. The results of day 6 were significantly (p=0.038) higher than that of the day 12 in the Si-HA group. Results of day 2 were also significantly (p=0.042) higher than that of the day 6 in the Sr1000-Si-HA group. When groups were compared to each other on day 2, the Sr 250-Si-HA and the Sr1000-Si-HA groups presented significantly (p=0.042) higher values than the HA group. On day 6, there were no significant differences between groups. On day 12, the Sr1000-Si-HA group had higher values than the Si-HA, the Sr250-Si-HA and the Sr500-Si-HA groups (p<0.001).
Figure 3.14. The ALP/DNA ratio of cells (a.u./µg) that were incubated with the ceramics.

Results were significantly (p=0.02) different between days 2-6, 6-12 and 2-12 in the BMP-HA group (Figure 3.15.). The day 6 results were higher (p=0.048) than that of the day 12 results of the BMP-Si-HA group. The day 2 results were also higher (p=0.048) than that of the days 6 and 12 results in the BMP-Sr500-Si-HA group. When the groups were compared to each other on day 2, the Sr500-Si-HA and the Sr1000-Si-HA groups had higher (p=0.042) ALP/DNA ratios than the other groups. On day 6, the BMP-Si-HA and the BMP-Sr1000-Si-HA groups had higher (p<0.001) results than the BMP-Sr500-Si-HA group. On day 12, the BMP-HA, the BMP-Sr250-Si-HA and the BMP-Sr1000-Si-HA groups had higher (p<0.001) ALP/DNA ratios than the BMP-Sr500-Si-HA group.
When BMP containing and not containing ceramics were compared on day 6, HA groups results were higher (p<0.001) than the BMP-Sr500-Si-HA group. Also, the BMP-Si-HA group had higher (p<0.001) values than the Sr500-Si-HA group. On day 12, the BMP-HA group had higher (p<0.001) ALP/DNA ratios than the Si-HA and the Sr500-Si-HA groups. In addition, the BMP-Sr1000-Si-HA group had higher (p<0.001) ALP/DNA ratios than the Si-HA and the Sr500-Si-HA group. The BMP-Sr250-Si-HA group had also higher (p<0.001) ALP/DNA ratios than the Sr500-Si-HA group. On the contrary, the Sr1000-Si-HA group resulted with a higher (p<0.001) ALP/DNA ratio than the BMP-Sr500-Si-HA group at same time point.

Cells that were grown on tcps had significantly different values at all time points (results of tcps were not shown in graphs). Cells which were
grown on tcps, showed significantly lower ALP/DNA ratios than Sr-Si-HA applied cells on day 2. However cells that were grown on tcps had higher results than other groups on day 6 and 12. Also, BMP applied cells resulted with lower ALP/DNA ratios than other BMP-containing ceramic groups on day 2.

3.3.5. SEM Images:

Attachment of cells to the ceramics had been detected after the MTT assay by SEM photography. Cell adhesions to the HA and the Sr500-Si-HA ceramics were obvious.

![Figure 3.16. SEM pictures of the cells that were incubated with the HA, the Sr250-Si-HA and the Sr500-Si-HA ceramics.](Figure 3.16)

CaP like precipitations were observed at cells that were incubated with the BMP containing ceramics (photos were not shown).

3.4. *In Vivo* Tests:

3.4.1. Radiology:

3.4.1.1. Periosteal Reaction Results:

Decrease in periosteal reaction was observed in the composite implanted groups. The BMP-Si-HA and BMP-Sr-Si-HA groups showed
significant (p=0.017) lower scores than the other groups at two weeks after bioceramic composite implantation (Figure 3.17.). The score of the control 2 group was higher than that of the other groups.

![Graph showing periosteal reaction results.](image)

**Figure 3.17.** Periosteal reaction results of the tibiae (control: defect only; control2: normal bone) of the groups.

3.4.1.2. Bone Union Results:

There were no significant bone union score differences between groups at the same time point. Bone union scores did not change along the experiments (Figure 3.18.).
**Figure 3.18.** Bone union scores of the tibiae (control: defect only; control 2: normal bone) of the groups.

3.4.1.3. Remodeling Results:

There were significant remodeling differences between groups two weeks after bioceramic implantation (Figure 3.19.). The BMP-Si-HA group had significant ($p=0.03$) lower scores than the HA, the Sr-Si-HA and the control 2 groups. The HA and the control 2 groups also had higher ($p=0.03$) remodeling scores than the BMP-Sr-Si-HA group at same time point.
Figure 3.19. Remodeling results of tibiae (control: defect only; control 2: normal bone) of the groups.

3.4.1.4. Implant Integration Results:

The HA, The BMP and/or Sr-containing Si-HA groups had lower implant integration scores than the Control 2 group (Figure 3.20.). The differences between groups at the same time points were not significantly different.
3.4.1.5. Overall Radiological Scores:

There were significant differences between groups two weeks after bioceramic implantation by means of periosteal reaction and remodeling. The BMP-Si-HA and the BMP-Sr-Si-HA groups had lower ($p=0.03$) scores than the HA, the Sr-Si-HA and the control2 groups.

**Figure 3.21.** Overall radiological scores of the tibiae (control: defect only; control 2: normal bone) of the groups.

78
3.4.2. DXA Results:

3.4.2.1. DXA Results of First Stage Experiments:

BMD values of the Si-HA ceramic implanted and defect created groups were not different than each other at all time points (Table 3.3.). Although tibiae BMD decreased from OVX to bioceramic implantation time, the differences were not significant. An increase in tibiae BMD values of the Si-HA implanted group was observed between bioceramic implantation and termination at 31 weeks time. The difference however was not significant again.

3.4.2.2. DXA Results of Second Stage Experiments:

BMD of the operated tibia measured by DXA improved after implantation in all groups (Table 3.4). The BMD of the tibia increased at most in the BMP-Sr-Si-HA group from composite implantation to termination at 4 weeks. BMD of the operated tibia also increased in the BMP-Si-HA and the Sr-Si-HA groups however changes were not statistically significant.

The BMD values of the femur and the vertebra were examined for evaluation of osteoporosis formation (Table 3.5. and Table 3.6.). According to the femur BMD results, BMD values of the OVX groups were decreased than that of the non-OVX group between OVX and implantation time. The difference was not significant statistically.
<table>
<thead>
<tr>
<th></th>
<th>Si-HA</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>ovx</td>
<td>0.304± 0.02 (0.252-0.325)</td>
<td>0.299± 0.0009 (0.298-0.3 )</td>
</tr>
<tr>
<td>oper</td>
<td>0.295± 0.02 (0.261-0.334)</td>
<td>0.289± 0.01 (0.272-0.298)</td>
</tr>
<tr>
<td>oper+2w</td>
<td>0.298± 0.01 (0.275-0.319)</td>
<td>0.294± 0.002 (0.291-0.297)</td>
</tr>
<tr>
<td>oper+4w</td>
<td>0.292± 0.02 (0.234-0.328)</td>
<td>0.297± 0.01 (0.282-0.313)</td>
</tr>
<tr>
<td>oper+8w</td>
<td>0.287± 0.004 (0.284-0.291)</td>
<td>0.292± 0.009 (0.281-0.302)</td>
</tr>
<tr>
<td>oper+17w</td>
<td>0.303± 0.015 (0.286-0.32)</td>
<td>0.299± 0.01 (0.29-0.316)</td>
</tr>
<tr>
<td>oper+31w</td>
<td>0.304± 0.007 (0.296-0.313)</td>
<td>0.288± 0.009 (0.278-0.3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>ovx</th>
<th>oper</th>
<th>oper+2w</th>
<th>oper+4w</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA</td>
<td>0.287± 0.02 (0.251-0.344)</td>
<td>0.264± 0.01 (0.238-0.286)</td>
<td>0.284± 0.01(0.266-0.308)</td>
<td>0.274± 0.02(0.251-0.308)</td>
</tr>
<tr>
<td>Si-HA</td>
<td>0.304± 0.02 (0.252-0.325)</td>
<td>0.295± 0.02 (0.261-0.334)</td>
<td>0.298± 0.01 (0.275-0.319)</td>
<td>0.292± 0.02 (0.234-0.328)</td>
</tr>
<tr>
<td>BMP-Si-HA</td>
<td>0.277± 0.015 (0.259-0.307)</td>
<td>0.264± 0.02 (0.231-0.293)</td>
<td>0.325± 0.04 (0.28-0.37)</td>
<td>0.287± 0.01 (0.272-0.296)</td>
</tr>
<tr>
<td>Sr-Si-HA</td>
<td>0.292± 0.02 (0.267-0.327)</td>
<td>0.252± 0.01 (0.229-0.289)</td>
<td>0.276± 0.02 (0.251-0.312)</td>
<td>0.279± 0.02 (0.262-0.305)</td>
</tr>
<tr>
<td>BMP-Sr-Si-HA</td>
<td>0.294± 0.02 (0.256-0.333)</td>
<td>0.267± 0.01 (0.251-0.292)</td>
<td>0.26± 0.008 (0.248-0.267)</td>
<td>0.304± 0.02 (0.279-0.319)</td>
</tr>
<tr>
<td>control</td>
<td>0.299± 0.0009 (0.298-0.3 )</td>
<td>0.289± 0.01 (0.272-0.298)</td>
<td>0.294± 0.002 (0.291-0.297)</td>
<td>0.297± 0.01 (0.282-0.313)</td>
</tr>
<tr>
<td>control2</td>
<td>0.284± 0.02 (0.253-0.329)</td>
<td>0.287± 0.02 (0.251-0.315)</td>
<td>0.290± 0.04 (0.261-0.349)</td>
<td>0.25± 0.01 (0.242-0.258)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>ovx</th>
<th>oper</th>
<th>oper+2w</th>
<th>oper+4w</th>
</tr>
</thead>
<tbody>
<tr>
<td>ovariectomized</td>
<td>0.333± 0.03 (0.284-0.391)</td>
<td>0.321± 0.02 (0.267-0.377)</td>
<td>0.323± 0.03 (0.287-0.379)</td>
<td>0.317± 0.02 (0.285-0.377)</td>
</tr>
<tr>
<td>non-ovariectomized</td>
<td>0.304± 0.01 (0.285-0.326)</td>
<td>0.322± 0.02 (0.288-0.344)</td>
<td>0.313± 0.03 (0.274-0.364)</td>
<td>0.314± 0.01 (0.306-0.322)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>ovx</th>
<th>oper</th>
<th>oper+2w</th>
<th>oper+4w</th>
</tr>
</thead>
<tbody>
<tr>
<td>ovariectomized</td>
<td>0.278± 0.01 (0.228-0.295)</td>
<td>0.277± 0.01 (0.249-0.298)</td>
<td>0.275± 0.008 (0.263-0.291)</td>
<td>0.271± 0.008 (0.253-0.287)</td>
</tr>
<tr>
<td>non-ovariectomized</td>
<td>0.274± 0.003 (0.272-0.279)</td>
<td>0.279± 0.0007 (0.279-0.28)</td>
<td>0.266± 0.01 (0.257-0.275)</td>
<td>0.28 ± 0.002 (0.278-0.282)</td>
</tr>
</tbody>
</table>
3.4.3. Micro CT:

Percent of bone volume/total volume (BV/TV) ratio of the bioceramic implanted defect area was calculated by micro CT and new bone formation was quantified. At 4 weeks, new bone formation had been observed at the edge of the defects. The BMP-Sr-Si-HA group leaded to new bone formation when compared to the HA group however the difference was not significant (Figures 3.22 and 3.23).

![Micro CT images of the ceramic implanted into cortical defect group (a, b) and normal bones (c, d).](image)

**Figure 3.22.** Micro CT images of the ceramic implanted into cortical defect group (a, b) and normal bones (c, d).

![Graph showing percent bone volume/total volume ratio results of samples that were bioceramic implanted.](image)

**Figure 3.23.** Percent bone volume/total volume ratio results of samples that were bioceramic implanted.
3.4.4. Histology and Histomorphometry:

In the first stage of *in vivo* experiments, effect of Si-HA ceramic was evaluated until 31 weeks after implantation. According to histological sections, the cavities in bone seemed ossified and the ceramic was biocompatible (Figure 3.24.).

![Figure 3.24.](#)

**Figure 3.24.** A to B (HE stained) and C to D (MT stained) show longterm (31week) implanted Si-HA ceramics. I: Implant, HE: Hematoxylin & Eosin, MT: Masson’s Trichrome.

Descriptive statistical data were presented in Table 3.7. for the bone defect healing measurements and the tissue response to the implant. No statistically significant difference was detected between the bioceramic implanted and the control groups regarding the defect healing parameters (defcbt/nbt and ntb/defarea) on weeks 2 and 4. Tissue response scores did
not differ between groups. Neither necrosis nor severe foreign body reaction was noted in any of the samples at any time point.

**Table 3.7.** Results of histomorphometrical analysis are presented as raw data. defcbt/nbt: ratio of cortical bone thickness at defect area to normal cortical bone thickness, ntb/defarea: ratio of the new trabecular bone area in the defect/total defect area).

<table>
<thead>
<tr>
<th></th>
<th>defcbt/nbt</th>
<th>ntb/defarea</th>
<th>tissue response</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 week</td>
<td>4 week</td>
<td>2 week</td>
</tr>
<tr>
<td>HA</td>
<td>0.389</td>
<td>0.766</td>
<td>0.460</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.714</td>
</tr>
<tr>
<td>BMP-Si-HA</td>
<td>0.370</td>
<td>0.919</td>
<td>0.573</td>
</tr>
<tr>
<td></td>
<td>0.495</td>
<td>0.967</td>
<td>0.676</td>
</tr>
<tr>
<td>Sr-Si-HA</td>
<td>0.548</td>
<td>0.831</td>
<td>0.578</td>
</tr>
<tr>
<td></td>
<td>0.476</td>
<td>0.805</td>
<td>0.636</td>
</tr>
<tr>
<td>BMP-Sr-Si-HA</td>
<td>0.776</td>
<td>0.844</td>
<td>0.577</td>
</tr>
<tr>
<td></td>
<td>0.704</td>
<td>0.865</td>
<td>0.745</td>
</tr>
<tr>
<td>Control(defect only)</td>
<td>0.273</td>
<td>0.471</td>
<td>0.226</td>
</tr>
</tbody>
</table>

On the other hand, the new bone per total defect area ratio and the cortical bone thickness ratio were higher in the bioceramic implanted groups comparing to that of the control (defect) group. The BMP-Sr-Si-HA, the BMP-Si-HA and the Sr-Si-HA groups provided better new bone formation rates when compared to the defect only and the HA groups at 2 week and 4 week (statistically not significant).

Diverse intramembraneous and at some areas stages of endochondral ossification were observed within the defect area of bioceramic implanted groups. The bioceramics provided an osteoconductive environment at the defect site initiating a mild inflammation that was characterized mainly by mononuclear phagocytic cells, lymphocytes and fibroblasts. The thin fibrous encapsulation consisted of thin collagen fibers with blood vessels adjacent to the degrading ceramic particles. The capsule allowed nearby new bone formation. The bioceramic particles are in close relation with the newly
forming bone trabecules in the implant groups. The bioceramics initiated the huge bony callus formations in all experimental groups (Figure 3.25.). The bioceramic particles being in close relation with the newly forming bone trabecules fill the ossified defect area, also the bony callus protrude into the marrow cavity and to the surrounding periosteum in the implant applied groups (Figure 3.26.).
Fig. 3.25. Endochondral (in D) and intramembranous (A-C, E-J) ossification steps are noted within the defect site of implant applied and control groups.
Fig. 3.26. The defect area is nearly totally ossified in all groups.
I: Implant, NB: New bone, CB: Cortical bone, BM: Bone marrow,
D: Defect, HE: Hematoxylin Eosin, MT: Masson’s Trichrome.
CHAPTER 4

DISCUSSION

XRD and porosity tests were conducted to characterize the ceramics. Compression strength measurement was performed to the ceramics after mechanical characterization.

According to the XRD results, the pattern of the HA ceramic ceramics were in agreement with the JCPDS. There were no peaks that belonged to CaO or TCP. This was a valuable result for supporting the Ca:P ratio. XRD peak intensities were lower in the Si-HA ceramics than the HA ceramics. This result was in line with other studies (Kim et al., 2003). Addition of Si into HA might have changed the peak intensity. XRD peak intensities decreased in the Sr250-Si-HA ceramics when compared to the Si-HA ceramics. Intensities however increased in the Sr500-Si-HA and the Sr1000-Si-HA ceramics. The reason for decrease in intensity of the Sr250-Si-HA was an unexpected result as the XRD results of the Sr1000-Si-HA ceramic was almost similar to that of HA. A possible explanation for the increase at intensities with Sr addition is that Sr is heavier and contains more electrons than Ca and scatter X-rays may occur more effectively (O'Donnell et al. (2008), Terra et al. (2009)). The X-ray pattern obtained from the Sr containing ceramics presented broader diffraction peaks as in other studies (Capuccini et al. (2009), Landi et al. (2007), Li et al. (2007), Li et al. (2010), Mardziah et al. (2008)). The broadening of the X-ray spectrum width indicated the incorporation of Sr to the structure (Li et al., 2007). Appearances of peaks at Sr-containing ceramics were also similar to the peaks obtained at the study of Dagang
(Dagang et al., 2010). Sr-100%HA which was sintered at 1200°C at that study had similar peaks at 2θ values (Dagang et al., 2010).

After XRD characterization, porosity percentages of ceramics were obtained. The bulk densities of ceramics seemed to be lower than the theoretical density of HA as these ceramics had 36.9 – 41.6 % porosity. Sintering conditions were thought to be the causative factor of this porosity range. Decrease in density of the materials may result in increase of biodegradability (Weiss et al., 2003) as density is closely related with porosity. HA materials that are fully dense are accepted to be biocompatible but resorb slowly in the body (Sun et al., 1998, 1999). Microporosity is necessary for cell ingrowth and nutrition when implanted into biological environments. Micropores were prerequisite for in vivo osteoconduction of CaP materials (Klawitter et al. (1971), Padilla et al. (2002), Chang et al. (2000), Lu et al. (1999). Expansion of osteoblasts onto porous surface of ceramics was observed in SEM photos in in vitro experiments. Our findings were in line with the study of Sennerby (Sennerby et al., 2005). Porosity is also an important factor for scaffold vascularization (Hing et al., 2004, 2005) and beneficial for biomineralization. Cellular events for bone formation occur on porous structures as can be seen from in vitro experiment results of this study.

Porosity test was performed in one sample and this was a limitation of our material characterization studies.

HA resulted with significantly lower compression strength (7.0 MPa) when compared to the other ceramics produced and evaluated in this study. Sr incorporation to Si-HA ceramics increased compression strength excluding the Sr500-Si-HA group (75.8 MPa). Sr1000-Si-HA ceramics had the highest compression strength (117.5 MPa) although significantly different result than the Si-HA ceramics was not obtained. Synthetic CaP has reduced mechanical properties because of increased porosity (Douglas et al., 2010). Sr-
incorporated HA based ceramic caused increase in compression strength and this finding was in line with that of the study of Guo (Guo et al., 2005). Compressive strength of HA materials decreased with the increase in sintering temperature according to researchers. The major problems of ceramic materials are their weak mechanical properties related with sintering conditions when compared with bone (Rezwan et al. (2006), Chen et al. (2006)). The compressive strength of HA in this study was significantly low. In Gupta’s study, different concentrations of Silica-CaP nanocomposites were evaluated (Gupta et al., 2007). The nanocomposite(diameter 13 mm x 8 mm) which had 32% porosity and lower Si% content than other groups achieved higher compressive strengths. In another study, compressive strength of 5% SiO₂-containing HA pellets(6mm diameter, 12mm height) was 79.09 MPa (Oktar et al., 2007). This value is lower than compressive strength of Si-HA ceramics of our study. Highly porous poly(L-lactic acid)(PLA) coated HA tube containing HA spherules(3–4 cm in length, 1–1.5 cm in diameter) was developed in Peng’s study (Peng et al., 2010). According to compression tests, pure HA scaffold had 0.28 MPa compression strength. However, in Cordell’s study PMMA-incorporated HA (6.36-6.48 mm in diameter, 12.7-13.1 mm in height) showed 110 MPa (Cordell et al., 2009). This value was higher than the strength obtained for HA in this study. Also, in another study (Dagang et al., 2010), Sr-100% HA group (inner diameter 10.5mm, height 17mm) had compressive strength value around 9 MPa with 44.2% microporosity. The Sr-containing material in this study had better compressive strength values although there were no differences between porosity percentages. Adding Sr to CaP materials enhanced compression strength values in another study (Dagang et al., 2010). The highest strength in this study was obtained with the Sr1000-Si-HA ceramics. In Liu’s study, compression strength of the Sr-HA materials(6 mm diameter, 12 mm length) was 144.5 MPa (Liu et al., 2010). Compressive strengths of human cortical bone and cancellous bone are 130-180 MPa (Seal et al. (2001), Keaveny et al. (1993), Zioupos et al. (1998)) and 2-12 MPa (Giesen et al. (2001), Yeni et
al. (2001)), respectively. In this study, Sr1000-Si-HA ceramics were found to be good option for bone replacement. Surface of the Si-HA ceramics was more regular than the other ceramic groups in this study. According to another study (Rosa et al., 2003) irregular surface topography formed on scaffolds when porosity increased. Mean crystal size was negatively effected when Sr amount increased in the ceramics (Verberckmoes et al., 2004). Sr incorporation to ceramics resulted with more disperse appearance when compared with other ceramics in this study. Similar dispersion was observed in the Sr-100%HA composites in another study (Dagang et al., 2010). Decrease in bone mineral crystallinity was evaluated as bone strength increased in Sr treated patients (Marie et al., 2001). Sr incorporation into HA ceramics resulted with adequate compression strengths which caused them to be preferred for bone replacement.

According to the released amounts of Sr from ceramics, Sr250-Si-HA and Sr1000-Si-HA showed consistent release between days 3 and 14. For Sr250-Si-HA the released Sr amount on day 14 was 125% of that of day 3. For Sr500-Si-HA released Sr amount on day 14 was 288% of that of day 3. And for Sr1000-Si-HA, released Sr amount on day 14 was 157% of that of day 3 in this study. Sr release from the ceramics were thought to present a linear increase until a threshold however according to our results, the Sr500-Si-HA ceramic presented a higher release than expected. In this study, the Sr1000-Si-HA ceramic retained the Sr in its structure. According to the Ca release test from ceramics, the Sr1000-Si-HA ceramic released higher Ca amount than the other Sr-containing groups (Figure 4.1.). If the Sr content replaced Ca in the content of the ceramics, this amount of Ca release from the Sr1000-Si-HA ceramics was accepted to be normal.
Figure 4.1. Ca release (mg/kg) from ceramics that were incubated in distilled water for 3 and 14 days (n=2 in all groups).

These results supported our selection of Sr1000-Si-HA ceramic for our \textit{in vitro} and \textit{in vivo} applications. Limitation of our Sr release test was the limited number of ceramics tested in this study. Furthermore Sr did not release from the ceramics in serum. This finding indicated that the release of Sr from bioceramics implanted to bone would be limited. Our initial aim for adding Sr into the bioceramics was not to release but improve biocompatibility. Therefore, the release rate of Sr was a descriptive finding for our study.

MTT test results presented deposition of cells on the ceramics. Increase at cell proliferation (based on higher cellular activity) had been observed until day 6 but decreased on day 12. Cells that were incubated with the Si-HA and the Sr250-Si-HA ceramics proliferated until day 6. However, on day 12, all ceramics showed decrease in cell proliferation rates. This indicated that cells reached to confluence or stopped dividing in a week. Higher absorbance was detected with the Sr1000-Si-HA ceramics on day 1.
The effect of Sr-250-Si-HA ceramic was significantly different than the other groups on day 6. Increase of cell proliferation rates in the Si-HA and the Sr250-Si-HA groups that were containing BMP were detected between day 1 and 6. The BMP-Si-HA composites also had higher proliferation rates than the BMP-Sr1000-Si-HA group on day 12. On day 1, cell attachment rate of the BMP-containing Sr1000-Si-HA composites was significantly higher than BMP free Si-HA group when BMP containing and not containing ceramics were compared. However, BMP-Si-HA and BMP-Sr250-Si-HA resulted with more proliferation rates on day 6. On day 12, HA ceramics resulted with more MTT absorbance than the other groups. According to the overall MTT results, BMP addition to ceramics enhanced cell proliferation rates at all time points excluding day 12. Although the Sr1000-Si-HA ceramics had significantly higher results on day 1, the Si-HA and the Sr250-Si-HA groups showed better results on later days. The Sr-HA ceramics showed better cell proliferation rates than the HA ceramics but the difference was not significant (Dagang et al., 2010). Boyd applied grafts containing different concentrations of Ca-Sr-Zn-Si-glass to fibroblast-like cells (Boyd et al., 2009). The graft that was containing higher amount of Sr caused the highest cell viability on day 7. On day 30 however cell viability decreased in the Sr containing grafts. Sr free grafts caused the highest cell viability at 30 days when compared to other grafts in that study. Authors explained this Sr related reduced cell viability by the effect of glass dissolution and accumulation of Zn-Sr in the medium with sequencing cytotoxicity. This finding was in line with our findings. Similarly, the Sr containing ceramics showed higher cell proliferation results at initial time points in this study. Sr free HA ceramics had better MTT absorbance than all the other groups on day 12. Although moderate proliferation rates were observed in the Sr1000-Si-HA ceramics on day 12 in this study, the HA ceramics which had higher Sr content resulted with better proliferation rates up to 14 days in another study (Capuccini et al., 2009). HA and TCP were compared in cell culture conditions in John’s study (John et al., 2009). Cell number on the HA scaffold
was lower than that of the TCP scaffold until day 28. Cell amount on the HA scaffolds however increased at later times (John et al., 2009). Si addition to the HA ceramics improved the cell proliferation rate further in this study. This result was in line with other studies and the role of Si for enhancement of bone function was reported before (Keeting et al. (1990), Reffitt et al. (2003)). Si-rich SCPC50 resulted with stimulation of osteoblast phenotypic expression (Gupta et al., 2007).

ALP activity of cells decreased with time in all but not the Sr1000-Si-HA group. MTT absorbance of the Sr1000-Si-HA group decreased during this period. However according to the ALP test, the results of day 12 almost reached the high results of day 2 of that the cells were incubated with the Sr1000-Si-HA ceramics. Sr1000-Si-HA ceramics triggered more ALP absorbance than the other ceramics on days 2 and 12 when groups were compared. According to the ALP test results of the BMP containing composites, the BMP-Sr1000-Si-HA composite had more ALP activity on day 2. ALP absorbance decreased in all BMP containing Sr-bioceramic composites on days 6 and 12. The BMP-Sr500-Si-HA composite resulted with the lowest ALP activity than the other groups on days 6 and 12. When BMP containing and not containing ceramics were compared on day 6, both the Sr500-Si-HA groups (BMP containing or not containing) again resulted with significantly lower ALP activities than the other groups. Besides, BMP-Si-HA composites showed higher ALP absorbance than the BMP free Si-HA, Sr500-Si-HA and Sr1000-Si-HA ceramics at the same time point. On day 12, BMP’s improving effect for ALP absorbance continued in the BMP-HA, BMP-Sr250-Si-HA and BMP-Sr1000-Si-HA groups. HA resulted with good ALP activity in this study. In a study (Nishio et al., 2000), pure Titanium (Ti) disks were compared with alkali-heat treated Ti(AH-Ti) or soaked AH-Ti (in simulated body fluid to deposit crystalline HA on the surface) disks and the ALP activities of cells that were incubated with all type disks were low at day 7. According to the XRD test, apatite layers formed on the soaked AH-Ti disks and higher ALP activity
was seen in cells than were applied with those disks than other type disks in that study. The raise in ALP activity might also be related to the Sr amount in the ceramics of this study. Sr1000-Si-HA’s stimulating effect could not be maintained until day 12 according to the MTT test. According to the ALP test, the Sr1000-Si-HA group resulted with good ALP absorbance rates. Capuccini investigated the effect of Sr-doped HA at OB like MG63 cells and Oc cultures (Capuccini et al., 2009). HA composites, which had higher Sr content, caused increase at cell proliferation rate and ALP activity in MG63 cells and decrease at proliferation of Oc(s) especially up to 14 days. Peng (Peng et al., 2009) had similar observations recently. ALP activity increased in higher amount of Sr applied groups on day 14 (Peng et al., 2009). According to the overall ALP results of this study, BMP addition to ceramics resulted with increased ALP activity of cells. Although BMP addition did not stimulate cell proliferation until day 12, its enhancing effect was observed in the ALP test. BMP effect to ceramics had been researched before (Watanabe et al. (1990), Ono et al. (1992, 1995), Takaoka et al. (1989), Urist et al. (1981)). Higher ALP activity was observed in the BMP-HA groups when compared to the BMP free HA groups in 2 weeks (Alam et al., 2001). Noshi also observed increased ALP activity by adding BMP to the HA with osteoblasts at 2 weeks (Noshi et al., 2001) which were in line with this study.

Cells that were incubated on tcps resulted with better in vitro values than cells applied with ceramics in this study. The effect of polystyrene on cell proliferation had been observed by Douglas et al in their study by comparing with HA-TCP microspheres (Douglas et al., 2010). They explained the reason as the flat surface form of tcps triggered more cell proliferation than 3D structure of biomaterials. This aspect can be valid for ceramics of this study, too. Porosity properties of ceramics may have affected the cell proliferation rates as well. According to some researchers (Anselme et al. (2000), Deligianni et al. (2001)), cell proliferation and ALP activity can be negatively influenced from irregular porous surfaces. Rosa applied HA discs with 5, 15, 30% porosity to cells in culture conditions (Rosa et al., 2003). HA
that had lower porosity percentage, which caused more cell proliferation at day 7 and 14 than other groups. Also, HA that had lower porosity percentage that resulted with higher ALP activity than HA having higher porosity percentage. According to researchers, cell response can be caused by difference of protein adsorption (Zeng et al., 1999) and reorganization of proteins on ceramic samples can be affected by physicochemical properties of the ceramic surface and their profile can be changed (Deligianni et al., 2001).

Although the Sr250-Si-HA and the Sr500-Si-HA ceramics showed lower DNA amount than the HA and the Si-HA ceramics on day 2, they showed higher results on day 6. Sr1000-Si-HA had moderate values at those time points. On day 12, the Sr1000-Si-HA ceramics triggered significantly higher DNA amounts than other ceramics. In addition, the BMP-Sr500-Si-HA composites showed significantly lower values than other composites on day 2. BMP-Si-HA composite caused higher DNA amount on day 6 and the BMP-HA group resulted with more DNA amount than the other groups on day 12. When BMP containing and not containing ceramics were compared, both the Sr500-Si-HA ceramics (BMP containing or not containing) had lower values than the other groups on day 2. BMP addition to ceramics enhanced the DNA amounts of cells especially in the BMP-Si-HA and the BMP-Sr250-Si-HA composites on day 6. These results were parallel to the MTT and the ALP test results. On day 12, although the BMP-HA composites had significantly higher DNA values, the BMP free Sr1000-Si-HA ceramics had better results than other ceramics. HA based material that have higher Sr amount triggered more cell proliferation rates in another study (Capuccini et al., 2009). Also, the DNA assay results of the Si-HA and the Sr250-Si-HA groups were parallel to that of the MTT assay. In addition, DNA test results supported the ALP test results for the Sr500-Si-HA ceramics.

According to the results of ALP activity per DNA of the cells, Sr1000-Si-HA and Sr250-Si-HA ceramics showed better results than the other
groups. BMP-Sr1000-Si-HA composites resulted with good percentages than some of the other groups. The ALP/DNA ratio of with soaked alkali-heat treated titanium disks was examined in another study (Nishio et al., 2000). Crystalline HA deposition on the surfaces of disks was aimed by soaking disks into simulated body fluid. The disks that had apatitic surface resulted with higher ALP/DNA ratio at days 7 and 14. Findings of Nishio et al. (Nishio et al., 2000) were similar to the findings of this study.

As a consequence of in vitro experiments, according to the MTT and DNA test results, BMP triggered proliferation rates of cells in initial time points. Sr1000-Si-HA ceramics caused more absorbance rates than other ceramics. Also, the Si-HA and the Sr250-Si-HA ceramics presented favorable MTT, DNA and ALP results. Osteoblastic cells showed typical polygonal shapes and adhered to the surface of the ceramics in SEM evaluations. The ceramics were processed for SEM analysis, however they waited for too long until SEM observation. Because of this reason, the cells on the ceramics could not be seen clearly. This was another limitation of our in vitro study. Sr500-Si-HA ceramics had lower absorbance values almost in all in vitro tests. According to the results of the Sr release test, the Sr500-Si-HA ceramic released more Sr than the other ceramics. Higher Sr release to the cell culture environment may have triggered the occurrence of the unexpected results. In Boyd’s study, decrease at cell viability thought to be related with the accumulation of zinc-Sr in the medium which resulted in cytotoxicity (Boyd et al., 2009). High amount of Sr accumulation in the medium might have affected the proliferation rates of cells in this study.

In vivo XP results of all groups had been evaluated for periosteal reaction, quality of bone union, remodeling, implant integration and total radiological scores at OVX, bioceramic implantation, 2 and 4 weeks after bioceramic implantation. For periosteal reaction and total radiological scores, the HA and Sr-Si-HA groups showed higher values than the BMP-Si-HA and BMP-Sr-Si-HA groups at 2 weeks after bioceramic implantation. Lower
radiological scores of the BMP-Si-HA group were observed at remodeling too. The control 2 group showed better results than the other groups in radiological scores at all time points as this group did not underwent OVX or defect operations. The scores of all bioceramic applied groups were around minimum 1 or 1.5. As the highest radiological score was 4, the results were considered as acceptable in this setting.

DXA results of femur and vertebra showed that, BMD values of the OVX groups were close to the non-ovariectomized group on 4 weeks after operation. OVX operations were applied to the rats for inducing osteoporosis. According to the DXA results, bioceramic implanted rats had increase in their BMD values 16 weeks after their OVX operations. However, limitation of the in vivo experiments in this study was the non statistical difference between time points.

According to micro CT analysis, BMP-Sr-Si-HA group had more new bone formation areas than the other groups 2 and 4 weeks after bioceramic implantation. This result was supporting DXA results of same group. But the differences between BV/TV% values of groups were not significant statistically. The effect of Sr addition to the scaffolds was observed using micro CT tests in other studies. In Li's study, Sr added HA group had higher BV/TV% than Sr absent group (Li et al., 2010). In Warnke's study, HA blocks were implanted to the rats (Warnke et al., 2010). Another implant was inserted to the rats later and BMP-2 was applied to both implants on second implantation time. According to CT observations of that study, lower bone densities were seen at delayed BMP-2 applied group. In this study, BMP-2 was applied to rats through composites simultaneously and BMP-2 added composites resulted in more BV/TV% values than other groups.

According to the results of histological investigation, the BMP-Sr-Si-HA, Sr-Si-HA and BMP-Si-HA bioceramic implanted groups resulted in higher new
bone formation rates than the other groups on 2 and 4 weeks. The HA implanted group showed lower bone formation rates than the other groups in this study. Similarly, in another study (Noshi et al., 2001) the alone HA ceramic did not trigger good histology results. In Noshi's study, HA, BMP-HA and MSC-BMP-HA materials were applied subcutaneously to rats (Noshi et al., 2001). HA and BMP-HA resulted without bone formation on 4 weeks after implantation. Besides, Sr addition was observed to increase new bone forming sites in another studies (Grynpas et al., 1996). Likewise, in this study Sr1000-Si-HA ceramics resulted with more bone formation areas. In this study, the Sr1000-Si-HA ceramics were preferred according to the in vitro test results. Also, the Si content of the ceramics might have increased new bone formation. According to some researches, Si enhanced solubility of HA (Porter et al., 2003) scaffolds. In addition, Si was known to improve bone mineralization and metabolism (Reffitt et al., 2003). In Uludağ's study, rhBMP-2-containing Helistat (colagen sponge) showed bone formation at 2 weeks (Uludağ et al., 2000). BMP addition to scaffolds enhanced bone formation while no bone formation areas were detected at BMP absent groups in another study (Alam et al., 2001). The results of this study were in line with that study. Enhancing effect of Sr was examined in other studies. Sr application resulted with increase at trabecular bone volume in Ammann’s study (Ammann et al., 2004). In Zreiqat's study, Sr–Hardystonite (Sr–Ca₂ZnSi₂O₇, Sr–HT) were compared to Hardystonite (HT) which were implantated to tibial bone defects of rats (Zreiqat et al., 2010). New bone formation areas were seen at periphery of Sr-HT implants on 3 weeks after implantation at that study.

According to observation of histological sections, mild inflammation with thin fibrous encapsulation was seen in this study. Ceramic particles mingled with bone and inflammatory reaction was not occurred. These results were important to show integration and biocompatibility of the bioceramics. Powder form of bioceramics might have affected the response of body. Because, CaP ceramics have risk to be accepted as foreign material by
immune system because of their brittleness properties (Anderson JM, 1988). Therefore, powder form of ceramics was preferred more against irritation of mucosal layers that could be formed by small particles of materials (de Groot K (1988), Douglas et al. (2010)).
CHAPTER 5

CONCLUSION

As a conclusion, we were able to prepare and characterize Sr containing ceramics and combined them with BMP in this study. The ceramics were evaluated by compression test mechanically after their characterization. According to our results, addition of Sr into Si-HA ceramics increased their compressive strength. Ceramics, which had more Sr content resulted with more compressive strength.

Sr release studies revealed that trace amount of Sr is released to distilled water in 3 and 14 days. However, Sr release into serum stayed under detection limits which indicated that the release of Sr from the ceramics will be limited when ceramics will be implanted into bone.

In vitro studies results showed that these ceramics were biocompatible. They stimulated rat OB proliferation. ALP activity and DNA amounts of cells increased parallel to the proliferation rate of cell especially in the Sr1000-Si-HA ceramic applied wells. In addition, BMP caused an increase in cellular activities when BMP was added into the ceramics.

In vivo results displayed that when BMP-Sr-Si-HA and Sr-Si-HA ceramics were implanted into rat tibia, they enhanced bone defect healing. Radiology was insufficient to quantify healing however micro CT and histological findings support in vivo biocompatibility and osteointegrity. Consequently, in this study, the ceramics displayed increased mechanical strength and allowed cell attachment (especially Sr-Si-HA ceramics). New bone formation increased with the BMP-Sr-Si-HA bioceramic composites in
bone defects. The results of this study promote future research on Sr containing bioceramics in treatment of orthopedic problems.
REFERENCES

2. Alam I, Asahina I, Ohmamiuda K, Takahashi K, Yokota S, Enomoto S. Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2, Biomaterials 2001; 22; 1643-1651
modulated by basic fibroblast growth factor. Anat Rec. 1997 Jun; 248(2); 198-204


16. Banerjee SS, Tarafder S, Davies NM, Bandyopadhyay A, Bose S. Understanding the influence of MgO and SrO binary doping on the
mechanical and biological properties of b-TCP ceramics, Acta Biomaterialia 2010; 6; 4167–4174


27. Brandi ML. Microarchitecture, the key to bone quality, Rheumatology 2009; 48; iv3–iv8
32. Bucholz RW. Nonallograft osteoconductive bone graft substitutes, Clin Orthop Relat Res. 2002 Feb; 395; 44-52
36. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro Bone 1996; 18(6), 517-23
47. Chen QZ, Thompson ID, Boccaccini AR. 45S5 Bioglass-derived glass-ceramic scaffolds for bone tissue engineering. Biomaterials 2006; 27(11), 2414–25
49. Chow J, Tobias JH, Colston KW, Chambers TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest 1997; 89(7), 1-8
52. Cordell JM, Vogl ML, Wagoner Johnson AJ. The influence of micropore size on the mechanical properties of bulk hydroxyapatite and hydroxyapatite scaffolds. Journal of the mechanical behavior of biomedical materials 2009; 2; 560-570
61. Deligianni DD, Katsala ND, Koutsoukos PG, Missirlis YF. Effect of surface roughness of hydroxyapatite on human bone marrow cell adhesion, proliferation, differentiation and detachment strength. Biomaterials 2001; 22; 87–96
63. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989 Apr; 4(2), 137-41
64. Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2006; 32; 617–629


75. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165(899), 1262-4

76. Frost HM. Dynamics of bone remodeling. In Bone Biodynamics, Boston: Little &Brown 1964; 315


83. Gentleman E, Fredholm YC, Jell G, Lotfibakhshaiesh N, O'Donnell MD, Hill RG, Stevens MM. The effects of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro, Biomaterials 2010; 31; 3949–3956
88. Grob GN. From Aging to Pathology: The Case of Osteoporosis. Journal of the history of medicine and allied sciences, 2010


97. Hearn AP, Silber E. Osteoporosis in multiple sclerosis, Mult Scler 2010; 16; 1031
103. Hing KA, Revell PA, Smith N, Buckland T. Effect of silicon level on rate, quality and progression of bone healing within silicate-substituted porous hydroxyapatite scaffolds, Biomaterials 2006; 27; 5014–5026


112. JCPDS, PDF card: no 9-432, ICDD(JCPDS) Newton square, Pennsylvania, USA


investigations of bone remodeling on a transparent hydroxyapatite ceramic, Biomed. Mater. 2009; 4; 015007, 9pp


120. Kamitakahara M, Ohtsuki C, Miyazaki T. Review Paper: Behavior of Ceramic Biomaterials Derived from Tricalcium Phosphate in Physiological Condition, J Biomater Appl 2008; 23; 197

121. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005; 16; 229-238


134. Köse N, Presentation slides, School of Basic Knowledge and Research about Orthopaedy and Traumatology, Turkish Orthopaedy and Traumatology Association, February 17-20, 2010.
147. Lewiecki EM. Managing osteoporosis: Challenges and strategies, Cleveland clinic Journal of Medicine, 2009; 76(8), 457-466
149. Li ZY, Lam WM, Yang C, Xu B, Ni GX, Abbah SA, Cheung KMC, Luk KDK, Lu WW. Chemical composition, crystal size and lattice structural changes after incorporation of strontium into biomimetic apatite, Biomaterials 2007; 28; 1452–1460
152. Liu C-C, Kalu DN. Human parathyroid hormone- (1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J Bone Miner Res 1990; 5; 973-82
153. Liu WC, Wong CT, Fong MK, Cheung WS, Kao RY, Luk KD, Lu WW. Gentamicin-loaded strontium-containing hydroxyapatite bioactive


158. Marcus CS, Lengemann FW. Absorption of Ca45 and Sr85 from solid and liquid food at various levels of the alimentary tract of the rat. J Nutr. 1962 Jun; 77; 155-60


164. Martin FC. Next steps for falls and fracture reduction. Age Ageing. 2009 Nov; 38(6); 640-3


197. Peng TC, Cooper CW, Munson PL. The hypocalcemic effect of alcohol in rats and dogs, Endocrinol 1972; 91; 586-593
198. Peng TC, Gitelman HJ. Ethanol-induced hypocalcemia, hypermagnesemia and inhibition of serum calcium-raising effect of parathyroid hormone in rats. Endocrinol 1974; 94; 608-611
200. Pi M, Quarles LD. A Novel Cation-Sensing Mechanism in Osteoblasts Is a Molecular Target for Strontium. J Bone Miner Res. 2004 May; 19(5), 862-9
201. Pors Nielsen S. The biological role of strontium. Bone 2004; 35; 583-88
204. Qiu K, Zhao XJ, Wan CX, Zhao CS, Chen YW. Effect of strontium ions on the growth of ROS17/2.8 cells on porous calcium polyphosphate scaffolds. Biomaterials 2006; 27; 1277–1286
206. Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens, Cytokine Growth Factor Dev 1997; 8C, 11-20

207. Reddi AH. Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am. 2001; 83-A Suppl 1(Pt 1), S1-6


211. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials 2006; 27(18), 3413–31

212. Rho JY, Kuhn-Spearing L, Zioupos P. Mechanical properties and the hierarchical structure of bone, Medical Engineering & Physics 1998; 20; 92-102


216. Rodríguez JP, Garat S, Gajardo H, Pino AM, Seitz G. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J Cell Biochem. 1999 Dec 1; 75(3), 414-23


233. Seeman E. Growth in bone mass and size are racial and gender differences in bone mineral density more apparent than real? J Clin Endocrinol Metab.1998 May; 83(5), 1414-9


Skoryna SC. Metabolic aspects of the pharmacologic uses of trace elements in human subjects with specific references to stable strontium. Trace Subst. Enviorn Health.1984; 18, 3-23


275. Westerlind KC, Wranski TJ, Ritman EL, Luo ZP, An KN, Bell NH, Turner RT. Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc Natl Acad Sci U S A. 1997 Apr 15; 94(8), 4199-204


131


286. Yeni YN, Fyhrie DP. Finite element calculated uniaxial apparent stiffness is a consistent predictor of uniaxial apparent strength in human vertebral cancellous bone tested with different boundary conditions. J Biomech 2001; 34; 1649–54

287. Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T, Cohort Profile: Research on Osteoarthritis/Osteoporosis


APPENDIX

ETHICAL COMMITTEE APPROVAL

HACETTEPE ÜNİVERSİTESİ
DENGE HAYVANLARI ETİK KURULU
Hacettepe 06100, ANKARA

Sayı : B.30.2.HAC.01.00.05/50

DENGE HAYVANLARI ETİK KURUL KARARI

TOPLANTI TARİHKI : 26.03.2007 ( PAZARTESİ )
TOPLANTI SAYISI : 2007/4
DOSYA KAYIT NUMARASI : 2007/32
KARAR NUMARASI : 2007/32 – 14
YARDIMCI ARASTIRMACILAR : Vet. Hek. Gâzide Kerman, Vet. Hek. Dr. İlyas Onbaşılar,
Prof. Dr. Feza Korkusuz, Prof. Dr. Mehmet Timuçin,
Prof. Dr. Aykut Özkul.

HAYVAN TÜRÜ VE SAYISI : 60 adet rat.


Prof. Dr. Halil Dağdeviren (Başkan)
Prof. Dr. Hakan Özer (Üye)
Prof. Dr. Sevim Dalkara (Üye)

KATILMADI
Prof. Dr. Semza Çalış (Üye)
Prof. Dr. Ömer Gündüz (Üye)

Doç. Dr. Nuket Özkol Büken (Üye)
Doç. Dr. Nuray Er (Üye)

Dr. Kaya Yorgancı (Üye)

Dr. V. H. İlyas Onbaşılar (Üye)

Avukat Oya Söyuer (Üye)
CURRICULUM VITAE

Personal Informations:
Name : Gözde
Surname : Kerman
Place of Birth : Ankara
Date of Birth : Jan 15, 1981
e-mail : gozdekerman@hotmail.com

Education Informations:
2004- : Middle East Technical University
         Natural and Applied Sciences-Biotechnology-PhD student
          Faculty of Veterinary Medicine
           Polatlı Anatolian High School-Polatlı/Ankara

Projects:
1. Kerman G, Bilgili H, Kürüm B, Yardımcı C, Soysal Y, Yıldız C, Deveci S,
   Bahçe M. Autologous Chondrocyte Transplantation:Clinical and
   experimental study in knee joints of dogs (Project results have been
   presented in 4th National Veterinary Medicine Students Research
   Congress(2002))

2. Kerman G, Yardımcı C, Pişkin E, Bilgili H. Biomechanical comparison of
   two different restoration techniques on cruciate anterior ligaments:
   Experimental study on rabbit knee joint (project results have been
   presented in 4th National Veterinary Medicine Students Research
   Congress(2002))

   Evaluation of MC3T3-E1 Cells applied to bioceramics by scanning electron
   microscope(SEM) and confocal microscope (CM) (Project results have
   been presented in 18th National Electron Microscope Congress(2007))

   Observation of MC3T3-E1 Cells Applied Bioceramics by Scanning Electron
   Microscope and Confocal Microscope(Project results have been presented
   11th Ceramic, Cells and Tissues Congress(2007))
Joined Congresses in Turkey:

- 4th National Veterinary Medicine Students Research Congress, May 9-11, 2002, Istanbul
- 2nd Eurasian IWRC Wildlife Rehabilitation Symposium, May 16-20, 2002, Ankara
- Basic course in Laboratory Animals Science, Nov 1-2, 2003, Kayseri
- 11th Biomedical Science and Technology Symposium, Sep 6-10, 2004, Hacettepe University, Ankara
- 4th Ankara University Biotechnology days, October, 2005, Ankara University, Ankara
- Nanotechnology Conference, NanoTR, May 3-5, 2006, Middle East Technical University, Ankara
- Cutting Edge Science in Medical Informatics and Medicine, June 22-23, 2006, Middle East Technical University, Ankara
- Immunohistochemistry Course, May 24-25, 2007, Hacettepe University, Ankara
- NanoTR III, Nanoscience and Nanotechnology Conference, June 11-14, 2007, Bilkent University, Ankara
- 18th National Electron Microscope Congress, August 26-29, 2007, Anadolu University, Eskisehir
- 3rd Stem Cell Symposium, October 5, 2007, Hacettepe University, Ankara
- Workshop on alternative methods (Reduction, Refinement, Replacement to Animal tests), Nov 12-13, 2007, Hacettepe University, Ankara
- Clinical Orthopaedics and Related Research Writing Workshop, April 18-20, 2008, Istanbul
- International Symposium on Biotechnology: Developments and Trends, September 27-30, 2009, Middle East Technical University, Ankara

Presentations in Congresses in Turkey:

- 4th National Veterinary Medicine Students Research Congress, May 9-11, 2002, Istanbul
- 18th National Electron Microscope Congress, August 26-29, 2007, Anadolu University, Eskisehir

Joined Congresses in Foreign Countries:

- 10th Biomedical Science and Technology Symposium, Oct 10-12, 2003, METU Campus of Northern Cyprus
Presentations in Congresses in Foreign Countries:

- 11th Annual Seminar and Meeting “Ceramics, Cells and Tissues”, October 2007, Faenza, Italy

Research experience:

- Experimental studies about cell culture and biomaterials, July 2004, Alberta University, Edmonton, Canada
- Experimental studies about cell culture, gene expression and biomaterials, June-August 2005, Alberta University, Edmonton, Canada
- Experimental studies about cell culture and bioceramics, March 2007, Selcuk University, Konya
- Experimental studies about cell culture, gene expression and biomaterials, July-August 2010, Alberta University, Edmonton, Canada

Publications:


Award:

- 4th National Veterinary Medicine Students Research Congress, Best Poster Award, May 9-11 2002, Istanbul

Languages:

- English: Upper-intermediate, TOEFL (CBT 227)
- German: Elementary level